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ABSTRACT 
 
Huntington’s disease (HD) is an autosomal dominant neurological disorder 
caused by a polyglutamine (polyQ) repeat expansion in the huntingtin (Htt) protein.  The 
disease is characterized by neurodegeneration and formation of neuronal intracellular 
inclusions primarily in the striatum and cortex, leading to personality changes, motor 
impairment, and dementia.  To date, the molecular mechanisms that underlie the 
neurodegenerative process remain to be defined.  Development of transgenic 
Drosophila HD models may facilitate dissection of molecular and cellular pathways that 
lead to disease pathology and suggest potential strategies for treatment. 
To explore mutant Htt-mediated mechanisms of neuronal dysfunction, we 
generated transgenic Drosophila that express the first 548 amino acids of the human Htt 
gene with either a pathogenic polyglutamine tract of 128 repeats (Htt-Q128) or a 
nonpathogenic tract of 0 repeats (Htt-Q0).  Characterization of these transgenic lines 
indicates formation of cytoplasmic and neuritic Htt aggregates in our Drosophila HD 
model that sequester other non-nuclear polyQ-containing proteins and block axonal 
transport. 
To further explore axonal transport defects in Huntington’s disease, we 
generated Drosophila transgenic strains expressing 588 aa or exon 1 N-terminal 
fragments of human huntingtin encoding pathogenic (HttQ138) or nonpathogenic 
(HttQ15) proteins tagged with mRFP and/or eGFP.  These transgenic lines enable in 
vivo imaging of Htt aggregation and trafficking in live Drosophila, providing a unique 
resource for tracking Htt in real time.  Our findings indicate that expression of mutant Htt 
may impair axonal transport through both aggregate-dependent and –independent 
means.   
Finally, to assay the therapeutic effect of expression of an intracellular antibody 
(intrabody) against Htt, we generated double transgenic lines coexpressing pathogenic 
Htt (mRFP-HttQ138) with the VL12.3 intrabody.  Intrabody expression caused 
suppression of aggregation in both neuronal and non-neuronal cell types, but failed to 
rescue mutant Htt-mediated cellular dysfunction.   
In summary, our Drosophila HD model provides an ideal in vivo system for 
examination of mutant Htt-mediated cellular defects, particularly impairment of axonal 
transport, and may facilitate rapid development and validation of potential treatments for 
Huntington’s disease. 
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Huntington’s disease: an overview 
 
Huntington’s disease (HD), a devastating autosomal dominant 
neurodegenerative disease affecting 1 in 10,000 (HDCRG, 1993), is the most common 
inherited neurodegenerative disorder.  The age of onset is highly variable; in most 
cases, onset occurs between the ages of 35-50, but HD has been reported in patients 
from the ages of 2 to >80 (Myers, 2004).  Symptoms of HD include involuntary 
choreiform movements and loss of motor coordination, cognitive impairment, and 
psychiatric disturbances, particularly depression. (Vonsattel et al., 1985).  Disease 
manifestation is progressive, with death occurring 15-20 years after onset of the first 
symptoms; earlier onset is usually associated with more rapid progression (Myers, 
2004).  At present, there is no cure. 
A substantial research effort has focused on neurodegenerative disorders 
caused by protein misfolding, including Huntington’s disease and other trinucleotide 
repeat disorders, Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral 
sclerosis and prion diseases.  Each disease is characterized by mutation and 
subsequent misfolding of specific protein(s), leading to the formation of intracellular 
inclusions and development of neuropathology in selective brain regions (Ross and 
Poirier, 2004).  In the case of polyglutamine (polyQ) repeat disorders, CAG expansions 
in the open reading frame of specific polyQ-tract containing proteins lead to nine known 
diseases, including Huntington’s disease, spinal and bulbar muscular atrophy (SBMA), 
dentatorubral and pallidoluysian atrophy (DRPLA), and spinocerebellar ataxias (SCAs) 
1, 3, 6, and 17.  With the exception of SBMA, all of the polyQ diseases are autosomal 
dominant and exhibit late-onset progressive neurodegeneration that roughly correlates 
with the formation of neuronal inclusions in regions of the brain specific to each disease 
(Ho et al., 2001b).  The selective vulnerability of neuronal subtypes is an ongoing 
question in polyglutamine disease research; although the causative proteins are 
expressed ubiquitously, characteristic patterns of neurodegeneration are seen in each 
disorder. 
In Huntington’s disease, pathology is characterized by atrophy of the caudate 
and putamen in the basal ganglia, as well as the cerebral cortex, reducing brain weight 
by up to 25-30% (Aylward et al., 1997; Rosas et al., 2002) (Fig. 1).  Most affected are 
GABAergic type II medium spiny projection neurons, which constitute about 80% of 
striatal neurons, and large neurons in layers III, IV, and V of the cortex (Hedreen et al., 
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1991).  Interestingly, striatal interneurons are spared (Zucker et al., 2005).  Medium 
spiny neurons receive glutamatergic signals from the cerebral cortex; defects in the 
basal ganglia-thalamocortical pathways involved in motor control may contribute to the 
choreiform disorders seen in HD (Albin et al., 1990). 
The Huntington’s disease gene, huntingtin (Htt), was mapped to chromosome 
4p16.3 in 1983, and the causative mutation was identified in 1993 as an expansion in a 
CAG repeat at the N-terminus of the protein, coding for a glutamine tract (HDCRG, 
1993).  In concordance with the other polyQ repeat disorders, the normal, 
nonpathogenic range for the polyQ tract in Htt is 6-35 repeats, while 36-39 repeats are 
variably penetrant, and expansion to greater than 40 repeats results in a fully penetrant 
disease phenotype (Rubinsztein et al., 1996).  An inverse correlation exists between 
polyQ repeat length and age of HD onset, with expansion past 70 glutamines resulting in 
a severe juvenile form of HD (Duyao et al., 1993; Telenius et al., 1993).  Pathogenic 
repeat lengths are unstable, with a bias towards expansion, especially during paternal 
transmission (Ranen et al., 1995).  This phenomenon, or “anticipation”, results in 
increasing severity of symptoms or earlier age of onset through successive generations 
(McInnis, 1996; Ross et al., 1993); as a result, most cases of juvenile HD are inherited 
from the father (Ridley et al., 1988).   
    Only 70% of the variability in age of onset can be accounted for by CAG repeat 
length (Ho et al., 2001b), suggesting the existence of genetic and environmental 
modifiers of HD.  Recent studies indicate that the size of the polyQ repeat in the normal 
Htt allele in HD patients influences the age of disease onset; surprisingly, in one report, 
larger polyQ repeats in the wild-type protein are correlated with later onset (Djousse et 
al., 2003).  Additionally, variations in the glutamate receptor 6 (GluR6) subunit of the 
kainate receptor are thought to affect the onset of symptoms.  A genome scan has 
identified other loci that may encode genetic modifiers (Li et al., 2003b).  Environmental 
factors may also play a role in mediating HD onset and progression, as suggested by the 
fact that monozygotic twins with polyQ repeats of identical length can exhibit different 
ages of onset and severity of HD symptoms (Anca et al., 2004; Georgiou et al., 1999).  
Environmental enrichment has been shown to delay the progression of motor symptoms 
and neuronal loss in mouse models of HD (Hockly et al., 2002; van Dellen et al., 2000), 
potentially by enhancing adult neurogenesis (Lazic et al., 2006; van Dellen and Hannan, 
2004).  Dietary restriction and supplementation with essential fatty acids may also delay 
disease onset in HD mice (Clifford et al., 2002; Duan et al., 2003). 
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Figure 1 
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FIGURE 1. Severe atrophy of the striatum and cortex in Huntington’s disease 
brain.  Particularly evident is loss of cells in the caudate (c) and putamen (p), resulting in 
enlarged lateral ventricles in HD brain.  (Reproduced from Marsh et al., 2003) 
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The structure and putative function of wild-type huntingtin 
 
Wild-type Htt is expressed ubiquitously in humans and rodents (Ferrante et al., 
1997; Fusco et al., 1999), and is particularly enriched in the brain (Cattaneo et al., 2005).  
The protein is predominantly cytoplasmic, and is localized to various subcellular 
compartments, including the ER, Golgi, neurites and synapses (DiFiglia et al., 1995; 
Hilditch-Maguire et al., 2000; Kegel et al., 2002; Li et al., 2003a; Velier et al., 1998), but 
may also have a role in the nucleus (Kegel et al., 2002).  Expression of Htt is essential 
for embryogenesis (Duyao et al., 1995; Nasir et al., 1995) and remains necessary 
throughout development (Bhide et al., 1996; Dragatsis et al., 2000; Nasir et al., 1995; 
Reiner et al., 2001) and in adulthood (O'Kusky et al., 1999), but the function of the Htt 
protein has yet to be conclusively identified. 
The Htt protein is comprised of 3144 amino acids, coding for a 348 kDa, 67 exon 
protein that shows little homology to other known proteins.  A polyQ stretch at the amino-
terminus of the protein is followed by a polyproline (polyP) tract and 37 putative HEAT 
repeats of about 40 aa in 3 clusters (Cattaneo et al., 2005).  Htt may also contain both a 
nuclear localization signal and a nuclear export signal, indicating that it may have a role 
in transporting molecules between the nucleus and cytoplasm (Xia et al., 2003) (Fig. 2).   
The structure of Htt allows it to interact with many binding partners; the polyQ 
tract, for instance, may bind to polyQ stretches in other proteins.  The polyP domain 
helps to maintain Htt solubility (Steffan et al., 2004) and interacts with Src homology 3 
(SH3) or tryptophan domains of other proteins, which are thought to include 
SH3GL3/endophilin 3 (Sittler et al., 1998), protein kinase C, PACSIN1 (Modregger et al., 
2002), p53 (Steffan et al., 2000), and PSD-95 (Sun et al., 2001).  The HEAT repeats are 
found in proteins involved in intracellular transport, microtubule dynamics, and 
chromosome segregation (Neuwald and Hirano, 2000) and form hydrophobic α-helices 
that assemble into a superhelix with a groove for interactions with proteins such as HIP1, 
HAP1, and HIP14 (Andrade et al., 2001; Harjes and Wanker, 2003; Li et al., 2006).   
The function of proteins known to interact with Htt may help to define its normal 
activity.  PolyQ- and HEAT repeat-containing proteins often play a role in regulation of 
transcription, and studies have shown interactions between Htt and various transcription 
factors such as the cAMP response-element binding protein (CBP) (McCampbell et al., 
2000; Steffan et al., 2000), p53 (McCampbell et al., 2000; Steffan et al., 2000), Sp1, 
TAFII130 (Dunah et al., 2002), N-CoR, and Sin3A (Boutell et al., 1999).  Htt may also 
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play a role in the cytoplasm; it associates with clathrin-coated vesicles and endosomal 
compartments, as well as with microtubules (Li et al., 2003c), indicating that it may play 
a role in clathrin-mediated endocytosis.  This possibility is underscored by the postulated 
interaction of Htt with proteins involved in endocytosis, such as HIP1, HIP12, PACSIN1, 
SH3GL3, and HIP14 (Harjes and Wanker, 2003).  Additionally, Htt is associated with 
both vesicles and proteins involved in vesicle transport, such as HAP1, which binds to 
the p150glued subunit of dynactin (Engelender et al., 1997; Li et al., 1998).  Htt and 
HAP1 are cotransported in both the anterograde and retrograde direction (Block-Galarza 
et al., 1997), indicating that Htt may function as an adaptor linking transport cargoes to 
motor systems.  The palmitoylation of Htt by HIP14, a palmitoyl transferase, supports the 
hypothesis that it is involved in vesicular trafficking; palmitoylated proteins are often 
involved in the regulation of vesicle transport and function (DiFiglia et al., 1995; Huang et 
al., 2004).  Htt may also function in post-synaptic signaling through interaction with PSD-
95, a scaffolding protein that links glutamate receptors and cytoplasmic signaling 
proteins (Sheng and Kim, 2002), and proteins that mediate dendritic morphogenesis 
such as CIP4 (Holbert et al., 2003) and FIP-2 (Hattula and Peranen, 2000).  Lastly, Htt 
binding to HIP1, which reduces the ability of HIP1 to induce procaspase-8 cleavage and 
apoptosis (Gervais et al., 2002), and Htt phosphorylation by the serine/threonine kinase 
Akt, a component in cellular survival pathways (Humbert et al., 2002), indicate that Htt 
may play an anti-apoptotic role in neurons.  
The discovery of several vertebrate and invertebrate Htt homologues has 
identified conserved domains that may be important for Htt function.  Homologues have 
been identified in mouse, rat, pufferfish, zebrafish, and Drosophila.  Htt is highly 
conserved among vertebrates, with greater than 90% peptide sequence identity to 
human Htt in rodents (Barnes et al., 1994; Schmitt et al., 1995); however, the polyQ 
repeat is greatly reduced, with only 7Q in mouse Htt (mHtt) (Barnes et al., 1994) and 4Q 
in pufferfish and zebrafish Htt (pHtt and zHtt, respectively) (Baxendale et al., 1995; 
Karlovich et al., 1998).  The polyQ and polyP regions are less conserved than the HEAT 
repeats (Takano and Gusella, 2002b), suggesting that binding of Htt interactors to HEAT 
superhelices may play a key part in normal Htt function.  The Drosophila homologue of 
Htt (dHtt) is the only entirely known invertebrate Htt sequence and is composed of 3583 
aa coding for a 394 kDa, 29 exon protein that is expressed throughout development and 
in the adult fly (Li et al., 1999b).  dHtt lacks polyQ and polyP tracts, as well as consensus 
caspase cleavage sites found in vertebrate Htts, but contains five regions of similarity to 
 16 
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FIGURE 2. Structure of wild-type huntingtin.  The polyglutamine and polyproline 
repeats are indicated by (Q)n and (P)n, respectively., while the nuclear export signal is 
identified by NES.  The red squares outline the locations of three main clusters of HEAT 
repeats.  Caspase cleavage sites are indicated by the green arrows, while calpain 
cleavage sites are marked by blue arrowheads.  Green and orange arrowheads show 
sites of protease cleavage selective for areas of the brain; A identifies regions cleaved in 
both the striatum and cortex, while B indicates regions preferentially cleaved in cortex 
and C indicates regions preferentially cleaved in striatum.  (Adapted from Cattaneo et 
al., 2005) 
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vertebrate Htt that may represent functional domains (Li et al., 1999b).  dHtt also 
contains 28 putative consensus HEAT repeats (Takano and Gusella, 2002b), 
underscoring the importance of these repeats in Htt function.  No Htt homologues have 
been identified in C. elegans, S. cerevisiae, or Arabidopsis thaliana (Takano and 
Gusella, 2002b). 
The polyQ repeat is conserved throughout vertebrate evolution, but is only highly 
polymorphic in humans (Cattaneo et al., 2005); concordantly, only humans develop the 
polyQ expansions in Htt that lead to Huntington’s disease.  The mechanism and effect of 
polyQ repeat expansion in the Htt protein are subjects of intense study. 
 
 
The role of mutant huntingtin in Huntington’s disease pathology 
 
The repeat instability of the polyQ tract found in Htt is thought to occur through 
defective replication, recombination and repair during gametogenesis.  Trinucleotide 
repeat sequences form unusual DNA structures prone to replication slippage when 
expanded past the disease threshold (Pearson et al., 2005).  The mutated protein then 
takes on an abnormal conformation that promotes formation of globular and protofibrillar 
intermediates (Fig. 3) (Poirier et al., 2002; Sanchez et al., 2003) that then assemble into 
SDS-resistant aggregates with a β-sheet conformation (Scherzinger et al., 1997); this 
type of amyloid structure is found in many late-onset neurodegenerative diseases, 
including Alzheimer’s disease, Parkinson’s disease, and the prion diseases (Ross and 
Poirier, 2004).  The precise β-sheet structure formed by aggregates of polyglutamine-
expanded proteins remains unknown; several potential structures are proposed by 
computer modeling (Fig. 4).   Aggregation may exhibit “seeded polymerization” kinetics, 
with a lag phase followed by a rapid growth phase (Chen et al., 2001; Scherzinger et al., 
1999).  The “polar zipper” hypothesis of aggregate formation states that polyQ tracts 
associate through hydrogen bonding between side-chain and main-chain amides, with 
self-interaction more rapid and energetically favorable for longer polyQ chains (Perutz, 
1996; Perutz et al., 1994).  There is also some evidence for formation of aggregates 
through the action of transglutaminases (Cooper et al., 1999; Zainelli et al., 2005), which 
catalyze formation of cross-linkages between glutamine and lysine residues. 
Much evidence suggests that the Htt protein is cleaved in vivo into N-terminal 
fragments, which are then able to form aggregates (Poirier et al., 2002); inclusions in HD 
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brain tissue are selectively labeled with antibodies to the N-terminus of Htt (Becher et al., 
1998; DiFiglia et al., 1997).  In most mouse and cellular HD models, N-terminal 
fragments of mutant Htt are more toxic than the full-length protein (de Almeida et al., 
2002).  The Htt protein contains three well-characterized caspase cleavage consensus 
sites (Goldberg et al., 1996; Wellington et al., 1998; Wellington et al., 2000) that are 
highly conserved in all vertebrate homologues of Htt (Goldberg et al., 1996; Wellington 
et al., 1998).  In addition, calpain cleavage sites are found in human and mouse Htt 
(Gafni and Ellerby, 2002; Gafni et al., 2004).  Mutant Htt is more susceptible to caspase-
and calpain-mediated cleavage, producing toxic N-terminal Htt fragments that are found 
in both the nucleus and the cytoplasm (DiFiglia et al., 1997; Kim et al., 1999; Lunkes et 
al., 2002).  Proteolytic processing appears to facilitate HD pathogenesis, as impairment 
of caspase and calpain activity reduces Htt toxicity and delays disease progression in 
cell cuture (Gafni et al., 2004; Ona et al., 1999; Wellington et al., 2000).  Phosphorylation 
at serines 421 and 434, which inhibits cleavage of Htt, is reduced in HD brain (Humbert 
et al., 2002; Luo et al., 2005; Warby et al., 2005).  Interestingly, Htt is cleaved at different 
sites in the cortex and striatum (Mende-Mueller et al., 2001), providing a potential reason 
for selective neuronal vulnerability in HD.   
An ongoing controversy in the field of HD research is whether HD pathology is 
caused by gain or loss of Htt function.  With the exception of SBMA, all of the polyQ 
disorders are inherited in an autosomal dominant manner, suggesting a gain of function 
in the disease protein.  However, haploinsufficiency of the normal allele or dominant 
negative activity of the mutant allele may contribute to disease pathogenesis.  
Inactivation of mHtt expression in the brains of adult mice results in a progressive 
neurological phenotype similar to that seen in transgenic mouse models of polyQ 
diseases (Dragatsis et al., 2000).  In addition, one-third of mice with a 50% decrease in 
full-length wild-type mHtt expression develop behavioral and cognitive abnormalities 
coupled with neurodegeneration in adulthood (Nasir et al., 1995; O'Kusky et al., 1999), 
suggesting that reduction in levels of normal Htt can lead to an HD-like pathology in the 
absence of an expanded polyQ protein.  Wild-type Htt has an anti-apoptotic function in 
neurons (Gervais et al., 2002; Rigamonti et al., 2000; Rigamonti et al., 2001); 50% or 
greater loss of this function may contribute to neuronal apoptosis see in human HD brain 
(Portera-Cailliau et al., 1995; Thomas et al., 1995) and in mHtt knockout mice (Dragatsis 
et al., 2000).  Compromising the role of normal Htt in production and transport of the 
neurotrophic factor BDNF (Zuccato et al., 2001) may also lead to neurodegeneration.
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Figure 3  
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FIGURE 3. Formation of intermediates and aggregates by mutant huntingtin.  
Mutation of the protein allows adoption of an abnormal conformation which then 
promotes sequential formation of globular intermediates, protofibrils, fibers, and SDS-
resistant inclusions.  (Reproduced from Ross and Poirier, 2004) 
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Figure 4 
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FIGURE 4.  Potential β-sheet models for expanded polyglutamine aggregates.  (A) 
Anti-parallel β-sheet “polar zipper” structure described by Perutz (Perutz et al., 1994).  
(B) Parallel β-sheet.  (C) Anti-parallel β-hairpin.  (D) Compact random coil containing 
four anti-parallel elements.  (E) Compact β-sheet structure consisting of four β-strand 
elements.  (F) Parallel β-helix structure with 20 residues per turn.  (Reproduced from 
Ross et al., 2003). 
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However, much evidence indicates that HD is not caused by a simple loss of wild-type 
Htt function.  Patients hemizygous for normal Htt do not develop any symptoms of HD 
(Ambrose et al., 1994).  In addition, expression of mutant Htt can rescue lethality in mHtt 
knockout mice (White et al., 1997), indicating that expansion of the polyQ tract does not 
cause complete loss of normal Htt function. 
More evidence exists for a gain of toxic function through expansion of the polyQ 
tract in the mutant Htt protein.  While expansion of the polyQ repeat in Htt does not 
abolish its function, insertion of a pathogenic polyQ repeat into HPRT, a protein not 
related to neurological disease, results in a late-onset neurodegenerative phenotype and 
premature death (Ordway et al., 1997), providing evidence for toxicity mediated by the 
expanded polyQ.  Transgenic mice expressing either full-length mutant Htt or an N-
terminal fragment of mutant Htt in addition to two wild-type alleles of mHtt develop signs 
of HD pathology (Hodgson et al., 1999; Mangiarini et al., 1996; Reddy et al., 1998; 
Schilling et al., 1999); knock-in mice in which the polyQ tract of mHtt has been expanded 
past the pathogenic threshold also exhibit HD-like symptoms (Lin et al., 2001; 
Shelbourne et al., 1999; White et al., 1997).  Additionally, expression of expanded polyQ 
proteins in C. elegans, which has no functional Htt homologue, is enough to produce a 
neurodegenerative phenotype (Faber et al., 1999).  Expansion of the polyQ repeat 
causes the Htt protein to assume an abnormal conformation, which may allow Htt to 
undergo abnormal associations with other proteins, including its self-association into 
aggregates.  Toxicity of mutant Htt may be mediated either by a soluble monomeric 
form, by protofibrillar intermediates, or by fully formed aggregates.   
While visible aggregates of mutant Htt are a hallmark of HD pathology, another 
hotly debated question in the field of HD research concerns whether the aggregates are 
harmful, neuroprotective, or neither; evidence exists for all sides, and is mostly 
correlative.  Resolution of this issue is important in deciding whether aggregation may be 
a target for HD therapeutics.  Evidence for aggregate-mediated pathology includes the 
correlation between the polyQ threshold for in vitro aggregation and the threshold for 
disease manifestation (Davies et al., 1997; Scherzinger et al., 1999).  Longer polyQ 
tracts undergo more rapid aggregate formation and require a lower critical concentration 
for aggregation, correlating with an earlier onset of disease symptoms (Chen et al., 
2001; Scherzinger et al., 1999).  Compounds that suppress aggregation, including 
chaperone proteins (Cummings et al., 1998; Warrick et al., 1999), chemical chaperones 
(Yoshida et al., 2002), small peptides (Kazantsev et al., 2002; Nagai et al., 2000), 
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intracellular antibodies (Colby et al., 2004a; Khoshnan et al., 2002; Lecerf et al., 2001), 
and drugs (Heiser et al., 2000; Wang et al., 2005), have also been found to suppress 
polyQ toxicity.  In addition, when the polyQ tract of the SCA1 polyQ disease protein is 
disrupted by insertion of histidine, aggregation is greatly reduced and the disease does 
not manifest (Sen et al., 2003).  In a conditional mouse model of HD, turning off Htt 
expression causes disappearance of nuclear aggregates and improvement in motor 
performance (Yamamoto et al., 2000).  Aggregates may cause pathology by 
sequestering various proteins, including mutant or wild-type Htt, away from their regular 
sites of function, or may disrupt or physically block cellular processes. 
However, other studies argue that aggregates play no role in polyQ-mediated 
pathology.  Evidence indicates that neurons exhibiting aggregates do not correspond 
entirely with neurons that undergo degeneration in HD; while some aggregates are 
found in medium spiny projection neurons of the striatum (Vonsattel et al., 1985), which 
are most vulnerable to neurodegeneration, more aggregates are found in striatal 
interneurons (Kuemmerle et al., 1999), which are spared.  A mouse model of HD 
expressing full-length mutant Htt exhibits a behavioral phenotype and neuronal cell loss, 
but little aggregation is observed (Hodgson et al., 1999; Reddy et al., 1998).  Some 
studies suggest that entry into the nucleus, rather than aggregate formation, is the cause 
of Htt toxicity (Bae et al., 2006; Peters et al., 1999; Saudou et al., 1998), and that 
aggregation may play a neuroprotective role by reducing the surface area with which 
aggregates can associate with other proteins.  In support of this neuroprotective 
function, aggregate formation correlates with a decrease in diffuse intracellular mutant 
Htt and an increase in cellular survival in neuronal culture (Arrasate et al., 2004).  In 
addition, disrupting ubiquitin conjugation suppresses aggregation but enhances toxicity 
in primary striatal neurons expressing mutant Htt (Saudou et al., 1998).  Visualization of 
neuronal nuclei in SCA1 and SCA3 brains show that nuclei appear healthier in neurons 
with visible aggregates than those without (Nagaoka et al., 2003; Uchihara et al., 2002), 
suggesting that aggregate formation may present a general mechanism to decrease 
toxicity of expanded polyQ disease proteins.  One hypothesis explains this 
neuroprotectivity as a result of stimulation of autophagy through aggregate-mediated 
sequestration of mTOR, a negative regulator of the autophagic pathway (Ravikumar et 
al., 2004).  Impairment of mTOR function may lead to subsequent degradation of toxic 
polyQ protein in the cytoplasm. 
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It remains a possibility that small “microaggregates”, rather than fully formed, 
visible aggregates, are the cause of HD pathology (Meredith, 2006).  Globular and 
protofibrillar intermediate structures found in HD (Poirier et al., 2002; Sanchez et al., 
2003) may be responsible for Htt toxicity, which may be decreased by assembly of the 
toxic intermediates into aggregates.  However, administration of the dye Congo red, 
which increases the ratio of protofibrils to aggregates, improves the behavioral 
phenotype and extends lifespan in transgenic HD mice (Sanchez et al., 2003), indicating 
that fully-formed aggregates of Htt are more toxic than intermediate structures. 
While it is likely that gain of toxic Htt function plays a key role in HD 
pathogenesis, at present it is impossible to rule out loss of wild-type Htt function as a 
contributing factor.  Use of animal models of HD may elucidate the normal function of 
Htt, the role of aggregates in HD pathology, and the cellular pathways affected in 
disease pathogenesis. 
 
 
Animal models of Huntington’s disease 
 
A range of animal models of HD have been developed to determine normal Htt 
function and to identify the molecular pathways affected in HD.  Such models are 
particularly useful to determine early, causative events in HD, as there is insufficient 
availability of brain tissue from presymptomatic HD patients to make studies possible.  
Genetic tools available in different model systems have made it possible to create a 
variety of knockout, transgenic, and knock-in models of HD. 
To date, mouse models of HD have been most commonly used for HD research.  
These models fall into three general categories: (1) homozygous or heterozygous knock-
out mice with inactivation of one or both mHtt alleles, (2) transgenic mice expressing 
truncated or full-length mutant human Htt, in addition to two wild-type alleles of mHtt, (3) 
mice with a pathogenic polyQ tract inserted into the existing polyQ tract (normally only 7 
Qs) of one allele of mHtt, in the presence of a wild-type mHtt allele. 
Studies using knock-out mouse models of HD have determined that Htt 
expression is essential throughout development and in adulthood.  Homozygous deletion 
of mHtt results in embryonic lethality before day 8.5 of embryogenesis, possibly due to 
defects in extra-embryonic tissue (Duyao et al., 1995; Nasir et al., 1995; Zeitlin et al., 
1995).  Htt is also necessary post-gastrulation; conditional inactivation of Htt expression 
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in the brain and testis of adult mice causes neurodegeneration and impaired 
spermatogenesis (Dragatsis et al., 2000).   
Several transgenic mouse models of HD have also been generated, expressing a 
range of N-terminal fragments or the full-length form of the human Htt protein with 
varying expansions in the polyQ repeat.  In general, toxicity of transgene expression is 
correlated with expression levels and with expansion size of the CAG repeat, and is 
inversely correlated with transgene length.  The most well-studied transgenic mouse HD 
model is the R6/2 mouse, which expresses exon 1 of human Htt with around 145 Qs 
(Mangiarini et al., 1996).  The R6/2 mouse exhibits a progressive behavioral and 
neuropathological phenotype with extensive formation of intranuclear and cytoplasmic 
aggregates (Davies et al., 1997; Li et al., 1999a), but without overt neuronal loss (Hockly 
et al., 2003b; Turmaine et al., 2000).  R6/1 mice, which harbor a shorter polyQ repeat of 
115 Q, exhibit slower disease progression with delayed formation of nuclear aggregates 
when compared to the R6/2 model (Davies et al., 1997).  N-171-82Q mice express both 
exons 1 and 2 of human Htt with 82 Qs (Schilling et al., 1999).  While the behavioral 
phenotype is more subtle in this model, the neuropathological profile more closely 
resembles that seen in HD brain, with a greater density of aggregates in cortical than in 
striatal neurons, but with more evidence of neurodegeneration in the striatum (Yu et al., 
2003).   
Mice expressing full-length human Htt with 48 or 89 Qs driven by the CMV 
promoter exhibit both a progressive motor phenotype and striatal neurodegeneration 
(Reddy et al., 1998).  A yeast artificial chromosome HD mouse model (YAC 128) 
expresses full-length human Htt with 128 Qs along with flanking genomic sequence that 
might contain Htt regulatory elements, and exhibits both motor defects and cortical and 
striatal neuronal cell loss correlating with behavioral abnormalities (Slow et al., 2003).  
Interestingly, very few aggregates are observed in full-length Htt-expressing mouse 
models, while even very low expression levels of truncated Htt lead to aggregate 
formation and a disease phenotype (Schilling et al., 1999), possibly highlighting the role 
of protein cleavage in HD pathogenesis. 
Knock-in mouse models of HD may be the most relevant for elucidating the role 
of the expanded polyQ repeat in the Htt protein, as the mHtt gene with an expanded 
CAG insertion is expressed under its natural promoter and in the proper genomic 
context.  A CAG repeat insertion of 72-80 in the polyQ tract of mHtt gene causes mice to 
exhibit aggressive behavior.  Neuropil aggregates are present, but no neuronal loss is 
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evident (Lin et al., 2001; Shelbourne et al., 1999).  Knocking in 94 CAG repeats results 
in progressive behavioral abnormalities accompanied by formation of nuclear 
microaggregates, but lifespan is normal (Menalled et al., 2002).  Insertion of 111 CAG 
repeats results in progressive formation of nuclear aggregates of N-terminal mHtt 
fragments in the striatum, with some striatal neurodegeneration observed, but no 
behavioral phenotype (Duan et al., 2003; Wheeler et al., 2002), while insertion of 140 
repeats leads to behavioral symptoms that precede the neuropathological phenotype of 
nuclear aggregrate formation in the striatum and neuropil aggregate formation in the 
globus pallidus and cerebral cortex (Menalled et al., 2003). Lastly, insertion of 150 CAG 
repeats results in motor impairment, striatal gliosis, and the development of striatal 
intranuclear aggregates (Lin et al., 2001).  The knock-in models exhibit alterations in 
molecular and cellular processes, but do not display overt neuronal loss, suggesting that 
neuronal dysfunction precedes neurodegeneration in HD. 
Invertebrate models of HD have also proven invaluable in disease research.  
While HD mouse models allow investigation of disease pathogenesis in a mammalian 
system that harbors more genetic and anatomical similarity to humans, invertebrate 
organisms such as the fruit fly Drosophila melanogaster and the nematode 
Caenorhabditis elegans provide many experimental advantages that are not available in 
more complex organisms.  These include small size, short generation time, and 
sophisticated tools for genetic and molecular manipulations.  While Drosophila and C. 
elegans are phylogenetically more distant from humans, many important cellular 
pathways are highly conserved (Bargmann, 1998; Yoshihara et al., 2001).   
Transgenic C. elegans models exist for Alzheimer’s disease (Link et al., 2001) 
and Parkinson’s disease (Nass et al., 2001), as well as for HD (Faber et al., 1999) 
(Parker et al., 2001).  Neuronal expression of N-terminal Htt fragments containing 88 or 
128 glutamines results in neuronal dysfunction (Parker et al., 2001), while expression of 
an N-terminal Htt fragment with 150 Qs leads to progressive degeneration (Faber et al., 
1999).  Both models exhibit formation of cytoplasmic aggregates. 
Several transgenic Drosophila models of polyQ disease have also been 
generated (Fernandez-Funez et al., 2000; Gunawardena et al., 2003; Jackson et al., 
1998; Kazemi-Esfarjani and Benzer, 2000; Lee et al., 2004; Marsh et al., 2000; Steffan 
et al., 2001; Takeyama et al., 2002; Warrick et al., 1999), and replicate many key 
features of the human diseases, including late-onset, progressive cellular pathology as a 
function of polyQ repeat length.  Fly models also exhibit behavioral phenotypes and 
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premature death.  Models commonly express a range of N-terminal mutant Htt 
fragments; expression of truncated mutant human Htt with 75 or 120 Qs in the fly eye 
leads to progressive neuronal degeneration in the absence of nuclear inclusions 
(Jackson et al., 1998), while pan-neuronal expression of either exon 1 or a 548 N-
terminal fragment of mutant human Htt results in formation of cytoplasmic and neuritic 
aggregates that disrupt axonal transport (Gunawardena et al., 2003; Lee et al., 2004). 
Invertebrate models of HD may prove invaluable in elaborating cellular pathways 
affected in HD.  Importantly, these models can be utilized to perform non-biased genetic 
screens to identify in vivo suppressors and enhancers that may provide insights into both 
normal Htt function and mechanisms of mutant Htt toxicity (Kazemi-Esfarjani and 
Benzer, 2000).  These organisms are also well-suited for in vivo testing of putative 
genetic and pharmacological Htt therapies (Kazantsev et al., 2002; Steffan et al., 2001; 
Zhang et al., 2005), and can be used for high-throughput screening of large compound 
libraries (Bates and Hockly, 2003).  Continued study of invertebrate HD models will 
contribute greatly to the elucidation of HD pathogenesis and treatment. 
 
 
Theories of Huntington’s disease pathogenesis 
 
The molecular pathways leading to HD pathogenesis have yet to be defined.  
Many cellular processes are proposed to play a key role in disease pathology; however, 
it is difficult to distinguish between early, causative events and secondary changes 
resulting from massive neuronal dysfunction.  In addition, it is likely that multiple 
pathogenic mechanisms, rather than a single initiating mechanism, contribute to HD 
onset.  Mutant Htt is found in both the nucleus and the cytoplasm of HD brain (Benn et 
al., 2005; Gutekunst et al., 1999); it is unknown whether toxic Htt activity occurs in the 
nucleus, in the cytoplasm, or in both.  Nuclear theories of HD pathogenesis focus mainly 
on transcriptional dysregulation, while toxicity of Htt in the cytoplasm may lead to 
ubiquitin/proteasome dysfunction, aberrant caspase activity, synaptic pathology, 
excitotoxicity, mitochondrial dysfunction, and/or impaired axonal transport. 
 
Transcriptional dysregulation 
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DNA transcription is a highly regulated cellular process that is impaired in HD, 
resulting in altered levels of expression for a number of genes.  Both wild-type and 
mutant Htt have been shown to interact with a range of transcription factors, giving rise 
to the hypothesis that abnormal interactions between mutant Htt and proteins involved in 
transcription lead to transcriptional dysregulation, which may be an early event in HD 
pathogenesis (Sugars and Rubinsztein, 2003). 
PolyQ repeats commonly occur in transcription factor proteins, suggesting that 
wild-type Htt may play a role in transcription via interaction with these proteins.  While 
Htt localizes mainly to the cytoplasm (DiFiglia et al., 1995), it has also been observed in 
the nucleus in human fibroblasts; mutant Htt in the nucleus has been shown to repress 
transcription (Kegel et al., 2002).  Mutation of Htt may result in dysregulation of 
transcription either through loss of normal Htt activity or abnormal binding of transcription 
factors by the mutant protein, leading to widespread alterations in gene expression.  
Analysis of HD brain reveals changes in gene expression profiles that are most 
pronounced in the caudate nucleus and the motor cortex (Hodges et al., 2006).  In a 
conditional PC12 cell model expressing exon 1 of mutant human Htt, transcriptional 
changes occur  within hours of turning on mutant Htt expression (Kita et al., 2002); these 
include decreased expression of genes involved in glucose and lipid metabolism and 
altered expression of genes involved in oxidative stress response.  Alterations in 
transcription are also seen in R6/2 mice, which exhibit downregulation of genes involved 
in transcriptional regulation, synaptic function, and calcium and retinoid signaling 
pathways, and upregulation of genes associated with cellular stress and inflammation 
(Luthi-Carter et al., 2000).  Less changes in expression levels are detected in mice 
expressing longer or full-length mutant Htt transgenes (Chan et al., 2002), suggesting 
that cleavage of Htt may be an important step in mediation of transcriptional 
dysregulation. 
Mutant Htt is observed to undergo abnormal associations with transcriptional 
regulators that include the cAMP response element binding protein binding protein 
(CBP) (Kazantsev et al., 1999; McCampbell et al., 2000; Nucifora et al., 2001; Steffan et 
al., 2000), TBP-associated factor II130 (TAFII130) (Shimohata et al., 2000), and 
specificity protein 1 (Sp1) (Shimohata et al., 2000); these proteins localize with Htt 
aggregates in HD brain, and disruption of transcriptional pathways mediated by these 
proteins is proposed to contribute to HD pathology.  Alterations in CRE- and Sp1-
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mediated transcription have received special attention, due to their roles in neuronal 
survival and neural gene expression, respectively. 
Many studies have focused on mutant Htt disruption of the function of the 
transcriptional coactivator CBP, a protein that functions in neuroprotective pathways.  
CBP associates with the cAMP response element binding protein (CREB) to activate 
transcription of cAMP-responsive genes, which mediate cellular stress responses and 
promote neuronal survival.  CBP contains a polyQ tract of 18 glutamines that allows for 
its interaction with mutant Htt through both its polyQ domain (Nucifora et al., 2001) and 
its acetyltransferase domain (Steffan et al., 2001), indicating that mutant Htt may inhibit 
both its transcriptional and acetyltransferase activity.  CBP has been detected in mutant 
Htt aggregates, and levels of soluble CBP are decreased in HD brain (Nucifora et al., 
2001), corresponding to downregulation of cAMP-responsive genes (Cha et al., 1999; 
Glass et al., 2000; Luthi-Carter et al., 2000; Timmers et al., 1996).  Downregulation of 
cAMP-responsive genes may contribute to a neurodegenerative phenotype; indeed, loss 
of CREB results in HD-like hippocampal and striatal pathology in mice (Mantamadiotis et 
al., 2002), and suppression of either CREB or CBP expression enhances polyQ toxicity 
in C. elegans (Bates et al., 2006), while CBP overexpression rescues polyQ toxicity in 
neuronal cell culture (McCampbell et al., 2000).   
The Sp1-mediated transcriptional pathway is also implicated in HD pathology; in 
HD brain, HD striatal neurons, and transgenic HD mouse brain, soluble mutant Htt is 
shown to have an enhanced interaction with Sp1, weakening its interaction with 
TAFII130 and with promoters for Sp1-mediated gene transcription (Chen-Plotkin et al., 
2006; Dunah et al., 2002).  This results in downregulation of genes that include the 
dopamine D2 receptor and nerve growth factor receptor genes (Dunah et al., 2002; Li et 
al., 2002).  Coexpression of Sp1 and TAFII130 in cultured striatal neurons from 
transgenic mice reverses alterations in transcription and protects neurons from polyQ-
mediated toxicity (Dunah et al., 2002). 
Recent studies indicate that wild-type Htt may regulate the nuclear transport of 
neuron-restrictive silencer element (NRSE) transcription factors, thus playing a role in 
regulation of genes that contain NRSE sequences.  NRSEs are found in genes 
responsible for neuronal development and function; suppression of NRSE-containing 
gene expression is mediated by the repressor element-1 transcription factor (REST) 
(Schoenherr and Anderson, 1995).  Wild-type Htt binds to REST in the cytoplasm and 
prevents it from entering the nucleus, allowing the expression of NRSE-containing 
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genes, including brain-derived neurotrophic factor (BDNF) (Zuccato et al., 2003).  
However, mutant Htt has an attenuated interaction with REST, leading to increased 
REST entry into the nucleus, where it inhibits expression of BDNF and other NRSE-
containing genes (Zuccato et al., 2003).  BDNF expression is reduced in the caudate 
and putamen of HD patients (Ferrer et al., 2000) and in the cortex and striatum of HD 
mouse models (Luthi-Carter et al., 2000; Luthi-Carter et al., 2002b; Zuccato et al., 2001), 
providing evidence for disruption of the interaction between Htt and REST.  Disruption of 
the important role of BDNF in neuronal survival and corticostriatal synaptic function 
(Ivkovic and Ehrlich, 1999; Jovanovic et al., 2000; Nakao et al., 1995; Widmer and Hefti, 
1994) may lead to neuronal dysfunction and striatal neurodegeneration.   
Mutant Htt may also cause transcriptional dysregulation by inhibiting the action of 
histone acetylases such as CBP, p300, and P/CAF through binding of the expanded 
polyQ tract to acetyltransferase domains (Steffan et al., 2001).  Acetylation of histones 
through histone acetyltransferase activity facilitates unwinding of chromatin, rendering it 
transcriptionally active; conversely, inhibition of histone acetylase activity results in 
repression of gene transcription.  Administration of histone deacetylase inhibitors 
rescues neurodegeneration in cellular, fly, and mouse models of HD (Ferrante et al., 
2003; Hockly et al., 2003b; Steffan et al., 2001), underscoring a role for mutant Htt-
mediated inhibition of histone acetylases in HD. 
 
Apoptosis/caspase activity 
 
Apopotosis is involved in the pathology of several neurodegenerative diseases, 
including Alzhemier’s disease and ALS, and has been suggested to play a causative role 
in Huntington’s disease.  Mutation of Htt may lead to HD through activation of caspases, 
which initiate and execute the apopototic program of cell death.  Signs of cell death, 
such as DNA fragmentation, have been observed in HD brain (Dragunow et al., 1995; 
Portera-Cailliau et al., 1995; Thomas et al., 1995), with the degree of fragmentation 
positively correlated with polyQ expansion length (Butterworth et al., 1998).  Additionally, 
expression of mutant Htt induces apoptosis in cell culture (Kim et al., 1999; Saudou et 
al., 1998).   Activation of caspases is observed in HD striatum (Ona et al., 1999; 
Sanchez et al., 1999) and in mutant-Htt expressing lymphoblasts (Maglione et al., 2006).  
An increase in caspase-1 activity is also observed in presymptomatic and early 
symptomatic transgenic HD mice, while inhibition of caspase-1 activity slows disease 
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pathology (Ona et al., 1999), indicating that caspase-mediated cell death may play a key 
role in initiation and progression of HD pathogenesis. 
Normal and mutant Htt are both cleaved into N-terminal fragments by caspase-1 
and caspase-3 (Goldberg et al., 1996; Wellington et al., 2002; Wellington et al., 2000); in 
a positive feedback loop, increased nuclear entry of N-terminal mutant Htt fragments 
then upregulates caspase-1 expression, leading to more Htt cleavage (Li et al., 2000b).  
Caspase-1 may then activate downstream effector caspases such as caspase-3, which 
can execute the apoptotic program (Li et al., 2000b).   Additionally, initiator caspases-8 
and -10 are auto-activated through sequestration into mutant Htt aggregates (Sanchez 
et al., 1999; U et al., 2001), while cytochrome c release from dysfunctional mitochondria 
found in HD activates caspase-9, (Kiechle et al., 2002), also triggering cascades leading 
to apoptosis.    
Mutation of Htt may also lead to apoptosis by diminishing the anti-apoptotic 
function of wild-type Htt.  Abnormally high levels of apoptosis are seen in Htt knockout 
mouse embryos, while overexpression of an N-terminal fragment of wild-type Htt 
provides protection against a range of apoptotic stimuli in neuronal culture (Rigamonti et 
al., 2000), including the pathogenic effect of mutant Htt exon 1 expression (Ho et al., 
2001a).  This neuroprotective effect may be due to wild-type Htt-mediated inhibition of 
pro-caspase-9 processing into active caspase-9 (Rigamonti et al., 2001).  Wild-type Htt 
also associates with the pro-apoptotic factor HIP-1, repressing its activation of caspase-
8-dependent cell death (Gervais et al., 2002; Hackam et al., 2000); mutation of Htt 
decreases this interaction and frees HIP-1 to induce apoptosis (Gervais et al., 2002).  
Lastly, Htt may be a component in a pro-survival pathway through phosphorylation by 
the serine/threonine kinase Akt (Humbert et al., 2002; Rangone et al., 2004).  Thus, if 
apoptosis plays a causal role in HD pathogenesis, both gain of mutant Htt function of 
loss of wild-type Htt function are likely to be involved. 
 
Chaperone and ubiquitin-proteasome dysfunction 
 
Normal cellular function requires the constant synthesis and degradation of 
proteins.  The correct folding of newly synthesized proteins into soluble conformations is 
mediated by chaperones; misfolded proteins are either refolded or tagged with ubiquitin 
for proteasomal degradation (Voges et al., 1999).  Impairment of chaperone or 
proteasome systems can lead to accumulation of misfolded or damaged proteins and 
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aggregate formation, inducing a cellular stress response that leads to cell death.  
Chaperone proteins such as heat shock proteins 70 (Hsp70) and 40 (Hsp40) interact 
with polyQ proteins and are recruited into Htt aggregates (Chai et al., 1999; Cummings 
et al., 1998; Wyttenbach et al., 2000), impairing their ability to regulate protein structure 
and contributing to cellular dysfunction and death.  Both polyQ aggregate formation and 
toxicity can be rescued by overexpression of chaperone proteins in neuronal culture 
(Chai et al., 1999; Kobayashi et al., 2000; Wyttenbach et al., 2000), Drosophila 
(Fernandez-Funez et al., 2000; Kazemi-Esfarjani and Benzer, 2000; Warrick et al., 1999) 
and mice (Cummings et al., 2001), indicating that mutant Htt-mediated loss of chaperone 
function may play a role in disease pathogenesis.  Evidence for proteasomal dysfunction 
in HD include inhibition of the ubiquitin-proteasome system in both early and late stage 
HD brain (Seo et al., 2004), as well as studies in which transient transfection of mutant 
Htt fragments severely impairs proteasomal degradation (Bence et al., 2001; Holmberg 
et al., 2004).  In addition, expression of expanded polyQ proteins renders neuroblastoma 
cells more vulnerable to additional cellular stress (Ding et al., 2002), and striatal neurons 
from R6/2 mice display increased pathology when subjected to oxidative stimuli 
(Petersen et al., 2001), suggesting mishandling of damaged proteins.  The extent of 
proteasomal dysfunction is correlated with polyQ expansion length (Jana et al., 2001), 
suggesting that a polyQ-related gain of mutant Htt function, such as aggregate 
formation, may be responsible for proteasomal impairment.  Indeed, Htt aggregates are 
ubiquitinated and associated with proteasome components (Ciechanover and Brundin, 
2003; Wyttenbach et al., 2000), indicating failed cellular attempts to degrade the 
misfolded Htt protein.  Because the ubiquitin-proteasome system plays a key role in 
regulation of cellular processes such as cell division and apopotosis, disruption of 
proteasome activity by mutant Htt may be a pathway to neuronal dysregulation and 
death. 
 
Synaptic dysfunction 
 
A specialized function of neurons involves transmission and reception of signals 
across the synaptic cleft.  Evidence of both pre- and postsynaptic dysfunction is 
observed in HD, and could underlie cognitive and motor symptoms of the disease.  
Decreased synaptic vesicle density and neurotransmitter release are seen in a 
transgenic HD mouse model (Li et al., 2003a), and may result from high levels of mutant 
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Htt in presynaptic terminals (DiFiglia et al., 1995).  Neurotransmitter release may be 
affected by abnormal associations between mutant Htt and presynaptic proteins such as 
complexin II, rabphilin 3A, and proteins involved in membrane endocytosis (Smith et al., 
2005).  After synaptic vesicle fusion to the plasma membrane and neurotransmitter 
release, endocytosis is necessary to recycle vesicle membranes and may also capture 
retrograde signals from the postsynaptic cell.  Expansion of the polyQ tract in Htt leads 
to its aberrant interaction with binding partners involved in endocytosis, binding more 
strongly to HAP1, PACSIN1, endophilin B1b, and SH3G13, and more weakly to HIP1 
and HIP14 (Smith et al., 2005).  Defects in endocytosis may result in both depletion of 
synaptic vesicles and loss of neurotrophic support from retrograde signals. 
Postsynaptic defects in HD may arise from impaired interaction between mutant 
Htt and the postsynaptic density protein PSD-95, a protein that plays a key role in 
regulation of synaptic plasticity and synaptogenesis (Che et al., 2000).  Wild-type Htt 
associates with the SH3 domains of PSD-95, a scaffolding protein that links NMDA and 
kainate receptors to the postsynaptic density (Sheng and Kim, 2002).  Mutation of Htt 
decreases its interaction with PSD-95, leading to NMDA receptor oversensitivity and 
excitotoxic cell death (Sun et al., 2001).  Other receptors are also affected by expression 
of mutant Htt; mGluR2 and 3 receptors and dopamine receptors are downregulated, and 
alpha-amino-3-hydroxy-5-methyl-4-proprionate (AMPA), kainate, and dopamine D1 and 
D2 receptors all exhibit decreased ligand binding in R6/2 mice (Cha et al., 1998). 
Electrophysiological evidence for synaptic pathology in HD include LTP defects 
in hippocampal slices from R6/2 HD mice (Murphy et al., 2000), YAC HD mice (Hodgson 
et al., 1999) and knock-in mice (Usdin et al., 1999), as well as LTD defects in R6/1 HD 
mice (Milnerwood et al., 2006).  Striatal neurons from R6/2 mice also exhibit more 
depolarized resting potentials (Levine et al., 1999), which may indicate removal of the 
voltage-dependent magnesium block of NMDA channels and vulnerability to excitotoxic 
neurodegeneration. 
 
Excitotoxicity 
 
Excessive glutamatergic input to the striatum from corticostriatal pathways may 
lead to glutamate excitotoxicity in HD.  Although cortical pyramidal neurons express 
higher levels of Htt than striatal cells (Fusco et al., 1999), overactivity of glutamate 
neurotransmission from cortical to striatal neurons may explain the selective vulnerability 
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of the striatum.  In addition, NMDA receptors are selectively depleted in the striatum of 
HD patients and asymptomatic carriers, suggesting that neurons responsive to 
glutamate neurotransmission are susceptible to neurodegeneration in HD (Albin et al., 
1990; Dure et al., 1991), and that this may be an early event in HD pathology.   
In excitotoxic cell death, binding of glutamate to NMDA receptors allows high 
levels of sodium and calcium to enter the neuron, activating calcium-dependent 
enzymes.  Some, such as nitric oxide synthase (NOS), increase free radical production 
(Nicotera et al., 1997), which can damage the cell and induce apoptotic or necrotic cell 
death.  An increase in intracellular calcium levels can also induce opening of the 
mitochondrial transition pore, which can release cytochrome C and apoptosis inducing 
factor (AIF) to activate cell death pathways (Susin et al., 1999).  Excitoxicity can be 
caused by either overtransmission of glutamate from presynaptic neurons, 
oversensitivity of receptors on postsynaptic neurons, or inefficient removal of glutamate 
from the synaptic cleft. 
Mutant Htt expression may affect cortical cells by decreasing expression of the 
metabotropic glutamate receptor mGluR2, which downregulates glutamate release at 
corticostriatal synapses; loss of mGluR2 receptors leads to overactive glutamate 
neurotransmission (Cha et al., 1998).  Excitotoxicity may also result from changes in 
postsynaptic striatal function.  In mouse HD models, increased sensitivity to NMDA 
receptor agonists is observed in neurons (Laforet et al., 2001; Levine et al., 1999), and 
administration of the NMDA agonist quinolinic acid to rats produces HD-like striatal 
lesions (Beal et al., 1991).  In addition, reduced mutant Htt binding to PSD-95 may also 
cause sensitization of NMDA receptors (Sun et al., 2001).  Lastly, decreased levels of 
the glial glutamate transporter GLT-1 are observed in transgenic HD mice (Behrens et 
al., 2002), suggesting that impaired glutamate handling by glial cells at the corticostriatal 
synapse may contribute to Htt-mediated excitotoxicity.  Blockage of glutamatergic 
corticostriatal inputs through decortication, glutamate release inhibitors, and NMDA 
receptor antagonists prevent the ability of mitochondrial toxins to produce HD-like striatal 
lesions (Schulz et al., 1996), further indicating a potential role for glutamate excitotoxicity 
in the selective striatal neurodegeneration seen in HD. 
 
Mitochondrial dysfunction and oxidative damage 
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Many studies have indicated that mitochondrial dysfunction may contribute to 
many neurodegenerative diseases (Beal, 2000), including HD.  Mitochondria are 
responsible for the synthesis of ATP, which is essential in neurons to fuel ionic pumps, 
antiporters, and ATP-dependent enzymes (Grunewald and Beal, 1999).  Mitochondria 
also buffer intracellular calcium levels and sequester apoptotic factors, playing a vital 
role in neuronal function and survival (Hollenbeck and Saxton, 2005).  Dysfunction of 
mitochondria can lead to metabolic insufficiency, oxidative damage, excitotoxicity, and 
neurodegeneration (Hollenbeck, 1996). 
Mitochondrial and metabolic defects are seen in several polyQ repeat disorders, 
including HD (Beal, 2000) and SCAs 1 and 3 (Mastrogiacomo et al., 1996; Matsuishi et 
al., 1996).  About half of Htt mutation carriers exhibit metabolic defects long before the 
onset of clinical symptoms (Antonini et al., 1996; Feigin et al., 2001), including severe 
chorea-independent weight loss (Djousse et al., 2002).  Positron emission topography 
(PET) scans of presymptomatic and symptomatic HD patients show a decrease in rates 
of glucose metabolism in the caudate nuclei and putamen, as well as in frontal, parietal, 
and striatal regions (Alavi et al., 1986; Goto et al., 1993; Hayden et al., 1986).  
Additionally, lactate levels are elevated in the basal ganglia and cerebral cortex of HD 
patients (Jenkins et al., 1998), suggesting an upregulation of glycolysis to compensate 
for defects in the oxidative phosphorylation pathway of ATP synthesis.  Lastly, the ratio 
of phosphocreatine to inorganic phosphate in HD resting muscle is inversely correlated 
with expansion of the polyQ repeat in Htt (Saft et al., 2005).  These metabolic defects 
point to a role for mitochondrial dysfunction in HD; defects observed in presymptomatic 
HD carriers indicate that mitochondrial impairment may be an early event in disease 
pathology. 
Ultrastructural studies indicate the presence of abnormal mitochondria in HD 
brain (Li et al., 2001) and in mutant Htt-expressing lymphoblasts (Squitieri et al., 2006), 
while appearance of degenerated mitochondria in the striatum of late-stage R6/2 mice 
corresponds with the onset of clinical symptoms (Yu et al., 2003).  Some evidence 
suggests that mutant Htt binds directly to the surface of mitochondria in R6/2 and YAC-
72Q HD mouse models (Panov et al., 2002; Yu et al., 2003), which may lead to a 
reduction in mitochondrial calcium uptake ability (Panov et al., 2002).  In addition, 
mitochondrial respiration and ATP production are greatly reduced in striatal cells from 
mutant Htt knock-in mice (Milakovic and Johnson, 2005), and biochemical studies show 
defects in complex II-III and complex IV activity in HD basal ganglia (Browne et al., 1997; 
 38 
Gu et al., 1996).  Further evidence for a role for dysfunctional mitochondria in HD 
pathology comes from the observation that systemic administration of mitochondrial 
toxins such as 3-nitropropionic acid (3-NP) and malonate, which selectively inhibit 
succinate dehydrogenase and mitochondrial complex II, induce striatal lesions and 
choreiform movement disorders in humans, rodents, and primates that strikingly 
resemble those seen in HD (Browne and Beal, 2002).  The striatal selectivity of many of 
these findings suggests that mitochondrial dysfunction may play a part in the 
neuropathological specificity of HD. 
Defects in mitochondrial membrane depolarization are observed in HD 
lymphoblasts, and lead to apoptotic cell death (Sawa et al., 1999); this may be due to an 
abnormal interaction between mutant Htt and p53.  Upregulation of p53 levels is seen in 
many neurodegenerative disorders (LaFerla et al., 1996; Martin, 2000), and has been 
observed in affected areas of HD brain and in neurons of transgenic HD mice.  Mutation 
of Htt strengthens its interaction with p53, resulting in elevated nuclear levels of p53 as 
well as increased p53 transcriptional activity and leading to mitochondrial membrane 
depolarization in HD neurons and lymphoblasts (Bae et al., 2005).  Loss of mitochondrial 
membrane potential impairs ATP synthesis and calcium handling in the neuron, leading 
to neuronal cell death (Ruan et al., 2004). 
Oxidative damage from mitochondrial dysfunction may also contribute to the 
disease state.  HD patients exhibit increased signs of oxidative damage in the striatum 
and cortex, including DNA strand breaks and elevated immunohistochemical staining of 
oxidative damage products (Browne et al., 1997; Polidori et al., 1999).  Reactive oxygen 
species are produced by oxidation-reduction reactions such as those that occur in the 
mitochondrial electron transport chain; free radicals formed by damaged mitochondria 
may attack lipid layers, proteins, and DNA, leading to cellular dysfunction and death 
(Calabrese et al., 2001).  3-NP-induced lesions and oxidative damage are reduced by 
expressing the free radical scavenger Cu/Zn superoxide dismutase (SOD1) (Browne and 
Beal, 2002), free radical traps, or nitric oxide synthase (NOS) inhibitors (Schulz et al., 
1995)  indicating a role for damage by free radicals in the formation of HD-like lesions 
and potentially in HD neuropathology.  Oxidative damage has also been found to 
downregulate genes involved in synaptic plasticity, vesicular transport, and mitochondrial 
function (Lu et al., 2004), leading to a widespread neurodegenerative phenotype.   
Many arguments can be made for mitochondrial dysfunction as an initial 
mechanism of HD pathogenesis, leading to impairment of other affected pathways.  
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Oxidative damage has been shown to enhance formation of mutant Htt aggregates 
(Goswami et al., 2006), potentially activating toxic pathways downstream of aggregation.  
Reduced ATP synthesis may trigger excitotoxicity by limiting the activity of ATP-
dependent ion pumps; loss of ionic and voltage gradients across the neuronal 
membrane may then relieve the voltage-gated magnesium block of NMDA channels, 
allowing ambient levels of glutamate to activate NMDA receptors and cause toxic influx 
of calcium (Grunewald and Beal, 1999).  ATP is also necessary as a precursor for cAMP 
synthesis; reduction in cAMP levels may decrease CRE-mediated transcription of genes 
involved in neuronal survival.  Lack of ATP and increased damage and misfolding of 
proteins due to ROS generation may also lead to insufficient activity of the ubiquitin-
proteasome system and impairment of its normal cellular function (Beal, 2005).   Mutant 
Htt may impair mitochondrial activity by interacting directly with mitochondria or by 
causing defects in mitochondrial transport. 
 
Axonal Transport 
 
Recently, many studies have highlighted a potential role for defective axonal 
transport in neurodegenerative disease.  Neurons rely on fast axonal transport to 
transport vesicles, organelles, nucleic acids, and signaling molecules between the cell 
body and the synapse via microtubule tracks (Schliwa and Woehlke, 2003).  The kinesin 
family of motor proteins mediates anterograde axonal transport to microtubule plus ends, 
while the dynein family mediates retrograde movement to microtubule minus ends with 
the help of the dynactin protein complex.  Impairment of axonal trafficking systems can 
have a devastating effect on neuronal function and survival. 
Axonal damage and defects in axonal transport have been implicated in a range 
of neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, 
motor neuron disease, and Huntington’s disease (Raff et al., 2002).  Indeed, mutations 
in motor proteins such as kinesin, dynein, and dynactin can themselves lead to 
neuropathological phenotypes (Hafezparast et al., 2003; LaMonte et al., 2002; Reid et 
al., 2002; Zhao et al., 2001).  Several lines of evidence indicate that wild-type Htt may 
play a vital role in axonal trafficking; Htt is associated with synaptosomal vesicle 
membranes (DiFiglia et al., 1995; Gutekunst et al., 1995), is transported in both 
anterograde and retrograde directions (Block-Galarza et al., 1997), and interacts with 
microtubules (DiFiglia et al., 1995) and the p150glued component of dynactin (via HAP1) 
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(Engelender et al., 1997; Li et al., 1998).  Mutation of Htt could disrupt axonal transport 
through abnormal protein associations or aggregate-dependent physical blockage of 
axons mediated by the mutant protein, or through loss of wild-type transport function.  
Many studies indicate that Htt aggregates in the axon may be involved in early 
HD pathogenesis.  Neuritic degeneration precedes cell body degeneration in cultured 
striatal neurons (Li et al., 2001), and is observed in presymptomatic HD patients (Albin et 
al., 1990).  In addition, formation of neuropil aggregates is more highly correlated with 
neuronal dysfunction than formation of nuclear aggregates (Li et al., 1999a).  In HD 
brain, mass spectrometry has shown that Htt aggregates sequester transport 
components such as α-tubulin, βΙΙΙ-tubulin, kinesin, and dynactin p150glued; the degree 
of this sequestration is correlated with disease severity and inversely correlated with 
neuronal survival (Trushina et al., 2004).  In addition, a subset of mutant Htt aggregates 
are observed to occupy almost the entire cross-sectional diameter of the axon (Li et al., 
2003a).  Correspondingly, aggregates have been shown to physically block the transport 
of exogenous markers (Li et al., 2001), synaptic vesicles (Lee et al., 2004), and 
organelles (Chang et al., 2006).  Bidirectional blockage of transport by aggregates may 
result in synaptic dysfunction, axonal degeneration, and cell death.   
Reduced transport velocity of axonal transport cargoes is observed in mice 
(Trushina et al., 2004), flies (Gunawardena et al., 2003), squid giant axon (Szebenyi et 
al., 2003), and neuronal cells (Chang et al., 2006; Gauthier et al., 2004; Trushina et al., 
2004) expressing mutant Htt, indicating a role for the mutant protein in impairment of 
transport.  In some studies (Szebenyi et al., 2003), decreased rate of transport is seen in 
the absence of neuritic aggregates, suggesting that the mutant protein may be able to 
cause aggregate-independent defects in transport.  Mutant Htt may cause transport 
defects by binding more tightly to HAP1 and p150glued, decreasing their interaction with 
microtubules and slowing movement of cargo that requires HAP1 for transport, such as 
the neurotrophic support molecule BDNF (Gauthier et al., 2004).   
While expression of mutant Htt leads to defects in axonal transport, inhibition of 
normal Htt function also impairs axonal trafficking in several models of HD.  Adult mice 
expressing less than 50% of the normal dosage of wild-type Htt exhibit defective 
trafficking of endocytic vesicles and mitochondria in both anterograde and retrograde 
directions, prior to onset of symptoms (Trushina et al., 2004).  In Drosophila 
(Gunawardena et al., 2003) and mammalian neurons (Gauthier et al., 2004; Trushina et 
 41
al., 2004), reduction of wild-type Htt levels leads to defective axonal transport of various 
cargoes, including vesicles, organelles, and BDNF.   
BDNF transport, as well as BDNF transcription, may be mediated by the wild-
type Htt protein (Gauthier et al., 2004).  BDNF colocalizes with Htt in cortical neurons, 
where it is transported to nerve terminals and released upon striatal neurons, triggering 
key signaling events (Mizuno et al., 1994; Ventimiglia et al., 1995).  Expansion of the 
polyQ tract in Htt reduces its ability to mediate BDNF transport; in addition, mutant Htt 
may disrupt the interaction between wild-type Htt and BDNF transport machinery 
(Gauthier et al., 2004; Saudou et al., 1998).  In HD patients (Ferrer et al., 2000) and 
R6/1 mice (Spires et al., 2004), BDNF is reduced in the striatum but not the cortex, 
suggesting a disruption in corticostriatal transport pathways that may result in excitotoxic 
death of striatal neurons.   
Disruption of wild-type Htt-mediated transport may also affect other cellular 
pathways.  Recent evidence indicates that impaired axonal transport of mitochondria 
may be particularly relevant to HD pathology.  Mitochondria normally undergo saltatory, 
bidirectional axonal transport, with individual mitochondria undergoing long stationary 
periods at target sites in the axon or at the synapse (Hollenbeck, 1996).  Proper 
distribution of mitochondria in the axon is essential to neuronal health; mitochondria with 
the high membrane potential necessary for ATP production move towards the synapse, 
while old or damaged mitochondria are transported back to the cell body for repair or 
autophagy (Miller and Sheetz, 2004).  Defects in mitochondrial transport may have a 
twofold effect: first, lack of healthy mitochondria at sites of high energy demand or tight 
calcium regulation, such as the axon and the synapse, may result in insufficient 
response to metabolic and calcium buffering needs, leading to neuronal dysfunction and 
death.  Second, failure to recycle aged or damaged mitochondria may lead to 
mitochondrial production of reactive oxygen species and release of cytochrome C, 
resulting in oxidative damage and apoptosis (Lee and Wei, 2000).   
Recent studies indicate that Htt may play a role in axonal trafficking of 
mitochondria.  A 50% decrease in wild-type Htt results in a decrease in the motility of 
mitochondria (Trushina et al., 2004).  Additionally, in flies lacking Milton, the Drosophila 
homologue of HAP1, mitochondria are prevented from entering the axon and remain in 
the cell body (Stowers et al., 2002), further suggesting a link between Htt and 
mitochondrial transport in the axon.  Expansion of the polyQ repeat may disrupt the 
normal role of Htt in trafficking of mitochondria, and may also lead to mutant Htt-
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mediated titration of normal Htt or other mitochondrial trafficking proteins.  Analysis of 
transport in HD cortical neurons (Chang et al., 2006) and in striatal neurons from 
transgenic HD mice (Trushina et al., 2004) reveals a significant decrease in 
mitochondrial movement, while degenerated mitochondria are seen in axons (Li et al., 
2001) and axon terminals (Li et al., 2003c) of transgenic HD mice, providing evidence for 
impaired transport of mitochondria in HD models.  Defects in mitochondrial transport, 
and resulting mitochondrial insufficiency and dysfunction, may lead to the excitotoxicity, 
oxidative damage, and neuronal cell death found in Huntington’s disease. 
 
 
Conclusion 
 
The wealth of evidence implicating a role for Htt mutation in numerous cellular 
pathways suggests that HD is a multifaceted disorder.  Pathology is likely to occur in 
both the nucleus and in the cytoplasm, and may be mediated by loss of wild-type 
function in concert with toxic activity of soluble and/or aggregated forms of the mutant 
Htt protein.  Further studies of the normal role of Htt and the cellular processes affected 
by mutant Htt may help to differentiate early pathological events from secondary ones; 
identification of causative pathways will facilitate the development of therapies to treat 
the disorder.  Many recent studies have focused on the role of wild-type Htt in axonal 
transport and in the role of mutant Htt in impairment of axonal transport.  In particular, 
defects in mitochondrial trafficking may play a key role in initiating many of the 
pathological phenotypes seen in Huntington’s disease.  Recent evidence suggests that 
expression of mutant Htt may disrupt axonal transport of mitochondria through loss and 
sequestration of the wild-type Htt protein and through physical blockage of transport by 
aggregates (Chang et al., 2006; Trushina et al., 2004); subsequent mitochondrial 
deficiency and dysfunction can lead to nearly all of the cellular pathology observed in 
HD, including transcriptional dysregulation, proteasome insufficiency, synaptic 
pathology, metabolic defects, oxidative damage, excitotoxicity, and apoptotic cell death.  
Here, we describe the characterization of a transgenic Drosophila model of HD and 
study of cellular processes altered by mutant Htt expression, with special emphasis on 
axonal transport.  Finally, we discuss the use of our Drosophila HD model for testing of 
potential therapies.  Findings from invertebrate models of human disease may lead to 
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greater understanding of basic disease mechanisms and suggest avenues for 
therapeutic development.   
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Abstract 
 
Huntington’s disease is an autosomal dominant neurodegenerative disorder caused by 
expansion of a polyglutamine tract in the huntingtin protein that results in intracellular 
aggregate formation and neurodegeneration.  Pathways leading from polyglutamine tract 
expansion to disease pathogenesis remain obscure.  To elucidate the means by which 
polyglutamine expansion causes neuronal dysfunction, we generated Drosophila 
transgenic strains expressing 548 aa N-terminal fragments of human huntingtin 
encoding pathogenic (Htt-Q128) or nonpathogenic (Htt-Q0) proteins.  While expression 
of Htt-Q0 has no discernible effect on behavior, lifespan, transcriptional regulation or 
neuronal morphology, pan-neuronal expression of Htt-Q128 led to progressive loss of 
motor coordination, decreased lifespan, altered gene expression and time-dependent 
formation of huntingtin aggregates specifically in the cytoplasm and neurites.  Huntingtin 
aggregates sequester other expanded polyglutamine proteins in the cytoplasm and lead 
to synaptic aggregate accumulation and disruption of axonal transport.  In contrast, 
Drosophila expressing an expanded polyglutamine tract alone, or an expanded 
polyglutamine tract in the context of the spinocerebellar ataxia type 3 protein, display 
only nuclear aggregates and do not disrupt axonal trafficking.  Our findings indicate that 
non-nuclear events induced by cytoplasmic huntingtin aggregation may play a central 
role in the progressive neurodegeneration observed in Huntington’s disease. 
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Introduction 
 
Huntington’s disease (HD) is characterized by neurodegeneration and formation 
of neuronal intracellular inclusions secondary to abnormal expansion of a CAG tract 
(encoding a polyglutamine repeat) in exon 1 of the huntingtin gene (Htt) (HDCRG, 1993).  
Expansion of the CAG tract past the pathological threshold of ~35-40 repeats ensures 
disease manifestation (Rubinsztein et al., 1996; Xuereb et al., 1996).  As with other 
glutamine-repeat disorders, abnormal protein conformation(s) promoted by 
polyglutamine (polyQ) expansion appear to be central to pathogenesis (Persichetti et al., 
1999; Scherzinger et al., 1997).  Although intracellular aggregates are a prominent 
hallmark of polyQ disease, their role in disease pathogenesis is debated (Kopito, 2000).  
In the case of HD, Htt-immunopositive aggregates have been observed in both the 
nucleus and the cytoplasm of affected neurons, although their primary subcellular 
localization remains controversial (DiFiglia et al., 1997).  One difficulty in characterizing 
the subcellular localization of Htt aggregates has been the widespread use of exon 1 
models, which encode only the first 81 amino acids of the Htt protein with the polyQ 
tract.  These models widely demonstrate nuclear localization of Htt-immunopositive 
aggregates.  Whether expression of exon 1 alone faithfully mimics the localization of the 
full-length endogenous protein (3144 amino acids) or its putative cleavage products is 
unclear.  However, if aggregate formation plays an essential role in disease progression, 
it is pertinent to determine the specific subcellular compartments in which aggregates 
produce detrimental effects.   
Although some evidence links intranuclear aggregates and disease manifestation 
(Becher et al., 1998; DiFiglia et al., 1997), recent findings suggest that the presence of 
aggregates in the nucleus may not be central to neuropathology (Gutekunst et al., 1999; 
Saudou et al., 1998).  HD disease symptoms have been reported to arise from neuronal 
cell loss before nuclear aggregates are detectable but after neuritic aggregates have 
appeared (Gutekunst et al., 1999; Sapp et al., 1999).  In transgenic mice, the presence 
of aggregates in neurites is highly correlated with development of neuropathological 
symptoms (Li et al., 1999a), and expression of the abnormal protein alters synaptic 
function (Lee et al., 2003; Li et al., 2000a; Murphy et al., 2000; Usdin et al., 1999), 
indicating that the toxic effects of mutant Htt expression may not be limited to the 
nucleus and may also cause defects in non-nuclear cellular processes. 
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A clearer understanding of cellular dysfunction mediated by expansion of the 
polyQ repeat in Htt can be gained by generating transgenic animal models of HD.  In 
particular, single-gene diseases such as the polyglutamine repeat disorders are well-
suited for modeling in Drosophila melanogaster.  The short generation time, small size, 
and genetic tractability of the organism, along with the high degree of conservation 
between mammalian and invertebrate cell biology, make Drosophila a powerful tool with 
which to explore basic molecular mechanisms of disease.  A key strength of Drosophila 
disease models is the ability to perform either hypothesis-driven or unbiased screens on 
a large scale for modifiers of disease phenotypes, as well as the potential for rapid 
validation of candidate therapies before testing in mammalian models.  Development of 
Drosophila HD models may thus facilitate the identification of both molecular pathways 
that lead to disease pathology and potential avenues for treatment. 
To explore mutant Htt-mediated mechanisms of neuronal dysfunction, we 
generated transgenic Drosophila that express the first 548 amino acids of the human Htt 
gene with either a pathogenic polyglutamine tract of 128 repeats (Htt-Q128) or a 
nonpathogenic tract of 0 repeats (Htt-Q0).  This N-terminal motif contains regions of 
strong homology between Htt isoforms from Drosophila to humans and is more likely to 
faithfully mimic endogenous Htt behavior than constructs containing only the first 81 
amino acids, which display no sequence conservation between Drosophila and human 
Htt homologs.  Our findings indicate the formation of cytoplasmic and neuritic Htt 
aggregates in our Drosophila HD model that sequester other non-nuclear polyQ-
containing proteins and block axonal transport. 
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Materials and Methods 
 
Drosophila Genetics and Generation of Htt Constructs 
Drosophila melanogaster were maintained on standard medium at 22oC.  cDNAs 
for Htt-Q0 and Htt-Q128 were generously provided by M. R. Hayden and subsequently 
subcloned into pHS or pUAST vectors.  Htt-Q0 was subcloned into 5’ Hpa I and 3’ Not I 
sites of pHS and into 5’ Eco R1 (blunt end ligation) and 3’ Not 1 sites of pUAST.  Htt-
Q128 was subcloned in 5’ Eco RI and 3’ Stu I (blunt end ligation) sites of pHS and into 5’ 
Eco R1 and 3’ Xba 1 (blunt end ligation) sites of pUAST.  The cDNAs encompass the 
start of the ORF of human Htt and terminate after amino acid 548 of the published 
sequence.  Transgenic animals were obtained through standard microinjection protocols.  
Confirmation of transgene expression was obtained by Western analysis with mouse 
anti-HD MAb2166 antibody against human Htt (Chemicon), which does not cross-react 
with the endogenous Drosophila Htt homolog.  Transgenic Drosophila encoding Q127 
were obtained from Parsi Kazemi-Esfarjani (Kazemi-Esfarjani and Benzer, 2000), SCA3-
Q78 from Nancy Bonini (Warrick et al., 1998) and Dishevelled-Q108 from Leslie 
Thompson (Marsh et al., 2000).   Transgenic lines expressing UAS-Htt and a second 
polyQ-encoding UAS transgene, or UAS-GFP, were generated through standard 
crosses. 
  
Western Blot Analysis  
To obtain samples for Western analysis of pHS-Htt lines, twenty Drosophila of 
each indicated genotype were collected and heat shocked at 37oC for 40 minutes, 
allowed to recover at room temperature for one hour, heat shocked again for 40 minutes, 
and incubated at 28oC overnight before processing.  Drosophila were frozen in liquid 
nitrogen and vortexed in order to isolate 20 heads for each genotype.  Heads were then 
homogenized in 50 μL of sample buffer and centrifuged for 5 seconds.  30 μL of the 
supernatant was added to 20 μL of sample buffer and boiled for 5 minutes.  10 μL per 
sample was loaded onto 10% SDS-PAGE gels and separated at 18 mA per gel.  The 
gels were immunoblotted with mouse anti-HD MAb2166 (Chemicon) at 1:1000, and 
immunoreactive bands were visualized using ECL (Pierce). 
 
Electroretinograms and DLM Flight Muscle Recordings 
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Extracellular recordings were made by placing a sharp glass electrode into the 
lateral thorax of adult animals, with the ground electrode in the Drosophila head.  Basal 
activity was recorded for 2 minutes at 20ºC.  Temperature shifts to 38ºC were then 
performed by heating the mounting clay in which the fly was embedded.  
Electroretinograms were performed as previously described (Littleton et al., 1998). 
 
Larval Locomotion and Adult Behavioral Analysis  
Wandering 3rd instar larvae grown at room temperature were collected, washed 
gently with distilled water, and placed individually on the center of a flat layer of 0.7% 
agar atop an evenly illuminated light box (Wang et al., 1997).  Larval locomotion was 
recorded with a digital video camera (CanonXL1S) attached to a 16x zoom lens.  
Recording stopped at 2.5 minutes or when the larva reached the edge of the agar layer, 
with documentation of the recording time.  Distance traveled by each larva was 
quantified by measuring the number of centimeters traversed by a crawling larva on the 
agar surface during the time recorded.  Speed was calculated by dividing the distance 
traveled by the number of seconds of recording time.  Drosophila viability assays were 
performed on elav-GAL4, Htt-Q128/white, Htt-Q128/elav-GAL4, and Htt-Q0/elav-GAL4 
flies by daily quantification of lethality for 200 female flies of each genotype.  Flies were 
aged at 25ºC, with twenty per food vial.  Food vials were transferred every two days. 
 
Microarray Analysis.   
Microarray analysis was performed with Affymetrix® high-density oligonucleotide 
GeneChip® arrays using the laboratory methods described in the Affymetrix® Genechip 
Expression Manual.  Transgenic flies were crossed to the elav-GAL4 driver, and RNA 
was isolated from adult male flies of the indicated genotypes aged for 3-4 days or 9-11 
days post-eclosion at 25oC.  Flies were frozen in liquid nitrogen and vortexed to isolate 
heads.  Circadian differences were minimized by processing tissue between 2 and 4pm.  
Total RNA was extracted from 600 pooled fly heads using the Trizol method (GIBCO-
BRL), with two independent RNA samples prepared from both 3-4 day-old flies and 9-11 
day-old flies for each genotype.  From the total RNA, poly(A) mRNA was isolated using 
the Qiagen Oligotex mRNA extraction kit and used as a template for cDNA via the 
Superscript Double-Stranded cDNA Synthesis Kit (Invitrogen).  Biotin-labeled cRNA was 
synthesized with biotinylated NTPs (Invitrogen), cleaned with the Qiagen RNEasy kit, 
and fragmented in fragmentation buffer (200mM Tris-acetate, pH8.1, 500 mM KOAc, 
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150 mM MgOAc) at 94oC for 35 minutes to produce 35-200 bp fragments for gene chip 
hybridization.  Affymetrix® high-density oligonucleotide arrays were probed, hybridized, 
stained and washed in the MIT Biopolymers Facility.  Microarray analysis was performed 
using the Affymetrix® Microarray Suite and Data Mining Tool statistics-based analysis 
software.  12 independent microarrays were analyzed (two each of RNA from 3-4 day-
old control, Htt-Q0-, and Htt-Q128-expressing flies, and two each of RNA from 9-11 day-
old control, Htt-Q0-, and Htt-Q128-expressing flies) for a total of eight pairwise 
comparisons between expression profiles from Htt-Q128-expressing flies and Htt-Q0-
expressing flies or control flies for both the 3-4 day set and the 9-11 day set.  Gene 
changes were called based upon the stringency criteria that differential regulation must 
be reported by Affymetrix® software for at least 75%, or twelve, of the sixteen pairwise 
comparisons for microarrays from both the 3-4 day set and the 9-11 day set.  In addition, 
the fold change in gene expression was required to be greater than or equal to 1.5 with a 
statistical significance of p<0.05 for either the 3-4 day set of the 9-11 day set.  
 
Morphological Analysis  
Immunostaining was performed on wandering 3rd instar larvae reared at 25ºC.  
Larvae were dissected in HL3 buffer (Stewart et al., 1994) and fixed in 4% formaldehyde 
in HL3 for 40 minutes at room temperature.  Primary antibodies used were mouse anti-
HD MAb2166 against human Htt (Chemicon) at 1:500, rabbit anti-GFP sc8334 against 
green fluorescent protein (Santa Cruz Biotechnology) at 1:500, anti-HA to label Q127 
and SCA3-Q78 at 1:1000, rabbit anti-Dishevelled (Willert et al., 1997) at 1:500, and 
rabbit anti-syt DSYT2 against Drosophila synaptotagmin (Littleton et al., 1993) at 1:500.  
FITC-HRP was used at 1:10,000 to label neuronal membranes. Visualization and 
quantification were performed on a Zeiss Pascal Confocal Microscope using Cy2-
conjugated and Rhodamine Red-conjugated secondary antibodies (Molecular Probes, 
Chemicon, Jackson Labs). Htt-Q128 aggregate diameter was determined by digitally 
capturing images at 40x and computing diameters (in μm) using LSM 5 Pascal Analysis 
Software.  All error measurements are STD unless otherwise indicated.  Corneal 
pseudopupil analysis of adult ommatidia was performed as previously described (Van 
Vactor et al., 1991). 
 
Electrophysiological analysis 
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Electrophysiological analysis of the neuromuscular junction in CNS-intact 
wandering 3rd instar larvae was performed in Drosophila HL3.1 saline solution (NaCl, 70 
mM; KCl, 5 mM; MgCl2, 4 mM; NaHCO3, 10 mM; trehalose, 5 mM; sucrose, 115 mM; 
HEPES-NaOH, 5 mM; pH 7.2) (Stewart et al., 1994) with an extracellular Ca2+ 
concentration of 0.2 mM as previously described (Montana and Littleton, 2004).  
Recordings were performed in muscle 6 in larval segments A3-A5.  All stimulus signals 
were generated through the pCLAMP v8.0 program (Axon Instruments) and data was 
analyzed using pCLAMP v9.0.  EJP analysis was performed by averaging ten evoked 
events from each muscle as one measurement and then averaging all measurements for 
each genotype.  Paired-pulse facilitation was analyzed by averaging ten first and second 
paired-pulse events from a single muscle, then dividing the average second EJP by the 
average first EJP for each timepoint.  mEJP analysis was performed using event 
detection analysis in pCLAMP v9.0. 
 
 
 77
Results  
 
Expression of a 548 aa N-terminal fragment of human huntingtin in a Drosophila 
model of Huntington’s disease 
To characterize neuronal defects that result from an expanded polyglutamine 
tract within the Htt gene, we generated transgenic Drosophila expressing N-terminal 
fragments of human Htt containing 0 (Htt-Q0) or 128 (Htt-Q128) glutamines. The Htt 
constructs were engineered to include the first 548 amino acids of the human Htt protein, 
which include and extend well beyond the 81 amino acid product encoded by the first 
exon of the gene.  While several models of HD have focused on expression of the 
polyglutamine-containing first exon of Htt alone (Jackson et al., 1998; Mangiarini et al., 
1996; Scherzinger et al., 1997; Steffan et al., 2001), the 548 amino acid fragment is 
truncated close to the site of cleavage by caspase-3, thought to be a crucial step in the 
generation of aggregate-forming Htt fragments (Kim et al., 2001; Wellington et al., 2002).  
This region also encompasses the highest stretch of homology between the Drosophila 
and human Htt proteins (Fig. 1A) (Li et al., 1999b), including protein interaction domains 
formed by HEAT repeats (Takano and Gusella, 2002a), providing a more accurate 
representation of the in vivo Htt protein context for the polyglutamine tract in our model.  
Two transgenic approaches were used to provide both temporal and spatial control of 
Htt gene expression.  First, the Htt-Q0 and Htt-Q128 fragments were expressed using 
the UAS/GAL4 binary expression system, allowing for transgene expression in the 
presence of the yeast GAL4 transcriptional activator in a tissue or cell type-specific 
manner.  In addition, Htt-Q0 and Htt-Q128 constructs were placed under control of the 
heat shock expression system, which enables temporal control of ubiquitous transgene 
expression following heat shock at 37oC.  We generated multiple independent 
transformant lines for each construct.  To confirm transgene expression in these strains, 
Htt protein expression was compared between pHS-Htt Drosophila maintained at room 
temperature and following exposure to a heat shock paradigm (Fig. 1B).  Western 
blotting with anti-human Htt antibodies detected no Htt protein in control Canton S or in 
pHS-Htt lines maintained at room temperature.  In contrast, Htt-Q0 and Htt-Q128 lines 
showed abundant Htt expression following heat shock.  As expected, the product 
detected in Htt-Q0 strains lacking the expanded polyglutamine tract is smaller than that 
in Htt-Q128 strains.  Similar results were obtained from pUAST-Htt strains crossed to a 
neuronal GAL4 driver (Fig. 1C).   
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FIGURE 1. Generation of a Drosophila transgenic model of Huntington’s disease.  
(A) Domain structure of the human and Drosophila Htt homologs with predicted HEAT-
like motifs indicated.  The 548 amino acid N-terminus of human Htt used for transgenic 
construction is indicated.  (B) Heat shock induction of Htt in Q0 and Q128 pHS strains.  
Western blotting was performed with an antibody generated to the N-terminus of human 
Htt that recognizes both the Q0 and Q128 variants.  (C) Expression of UAS-Htt-Q0 and 
UAS-Htt-Q128 with the pan-neuronal elav-GAL4 driver.  Western blotting was performed 
with an antibody against the N-terminus of human Htt.  (D, E). External morphology and 
pseudopupil analysis of transgenic Drosophila expressing either Htt-Q0 (C) or Htt-Q128 
(D) driven by the eye-specific GMR-GAL4 driver.  Flies were aged for 2-4 days at 25ºC 
prior to analysis. Htt-Q128 causes a rough-eye phenotype with loss of pigmentation, 
abnormal bristle pattern and photoreceptor degeneration. 
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To determine the functional consequences of Htt-Q128 expression on neuronal 
activity and morphology, we first examined effects in the visual system.  Previous 
Drosophila models of polyglutamine diseases have demonstrated that eye-specific 
expression of expanded polyQ proteins leads to a rough-eye phenotype and 
photoreceptor degeneration (Fernandez-Funez et al., 2000; Jackson et al., 1998; 
Kazemi-Esfarjani and Benzer, 2000; Marsh et al., 2000).  To determine if the 548 amino 
acid Htt transgene caused similar effects, Htt-Q0 and Htt-Q128 were expressed using 
the eye-specific GMR-GAL4 driver and the resulting eye phenotypes were observed by 
external morphology and by the corneal pseudopupil method, an optical technique that 
allows assessment of photoreceptor patterns in the ommatidia.  While expression of Htt-
Q0 did not perturb external eye appearance or ommatidial morphology (Fig. 1D), 
expression of Htt-Q128 caused a rough-eye phenotype with corresponding 
photoreceptor degeneration (Fig. 1E).  These results suggest that polyglutamine 
expansion in the context of a larger Htt fragment results in neurodegeneration, as 
observed in other polyglutamine disease models. 
 
Mutant Htt induces electrophysiological defects in the eye and the giant fiber 
flight circuit 
To characterize the physiological effects of mutant Htt expression, we recorded 
electroretinograms (ERGs) from transgenic animals (Fig. 2A).  ERGs are extracellular 
recordings of photoreceptor depolarization and on/off transients thought to represent 
synaptic transmission in response to light.  A normal electrical response to light was 
seen in Drosophila expressing the GMR-GAL4 driver alone, Htt-Q0 with GMR-GAL4, or 
Htt-Q128 without the GMR-GAL4 driver.  In contrast, Drosophila expressing Htt-Q128 
with the GMR-GAL4 driver showed reduced photoreceptor depolarization and complete 
abolishment of on/off transients in response to light.  Similar abnormal ERGs were 
observed in heat-shocked pHS-Htt-Q128 lines following a developmental heat shock 
paradigm, but not with control pHS-Htt-Q0 strains (Fig. 2A).  The defective ERGs 
confirm that Htt-Q128 disrupts photoreceptor viability and function, and suggest 
abnormal synaptic transmission in the visual system. 
 To further analyze defects in neuronal activity, electrophysiological analysis was 
performed in the giant fiber flight circuit, a pathway important in escape responses and 
flight initiation.  The pathway can be activated by stimulation of the brain and 
extracellular recordings can be made from the dorsal longitudinal flight muscles (DLMs).  
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Wild type Drosophila display little to no spontaneous activity when the temperature is 
raised to 38ºC.  In contrast, previously isolated neurodegenerative mutants (Palladino et 
al., 2002) have demonstrated robust spontaneous seizure activity in the DLM flight 
muscles at 38ºC.  Similar seizure activity was recorded in Htt-Q128 flies at 38ºC 
following a developmental heat shock paradigm (Fig. 2B).  In contrast, no seizure activity 
was recorded in Htt-Q0 flies at 38oC (Fig. 2B).  Together, these results suggest that Htt-
Q128 expression results in neurodegeneration, accompanied by widespread defects in 
membrane excitability and brain activity. 
 
Mutant Htt causes behavioral phenotypes in Drosophila at larval and adult stages 
To establish whether neuronal Htt-Q128 transgene expression causes defects at 
earlier stages of Drosophila development, we performed quantitative locomotion assays 
to examine the function of the motor central pattern generator in 3rd instar larvae.  
Drosophila larvae move by performing rhythmic waves of body wall muscle contraction 
and elongation, resulting in peristaltic propagation.  Locomotor behavior depends on 
central pattern generators that organize and produce specific patterns of activation and 
inhibition of motor neurons.  To determine if Htt-Q128 altered larval locomotion, we 
assayed larval crawling speed in transgenic animals.  When Htt transgenes were 
expressed with the pan-neuronal elav-GAL4 driver C155, Htt-Q128 larvae showed a 
significant decrease in distance traveled, corresponding to a >25% reduction in 
locomotor speed from 1.23 mm/sec in control Htt-Q0 animals to 0.92 mm/sec in Htt-
Q128 larvae (Student’s t-test, p<0.001, Fig. 2C).  These behavioral abnormalities 
suggest that Htt-Q128 has significant effects on motor output, consistent with abnormal 
neuronal function secondary to Htt-Q128 expression.   
 Adult transgenic flies also display abnormal motor behavior caused by pan-
neuronal expression of the Htt-Q128 protein.  While expression of Htt-Q128 with the 
C155 neuronal GAL4 driver causes pharate adult lethality with no viable adult escapers, 
Htt-Q128 driven by a weaker 2nd chromosome elav-GAL4 driver results in fully viable 
adults.  However, several days after eclosion, flies expressing Htt-Q128, but not Htt-Q0, 
begin to display uncoordinated movement and abnormal grooming behaviors.  The 
behavioral defects worsen with age, eventually resulting in premature death.  To quantify 
the reduction in viability, lifespan curves were generated for control adults, Htt-Q128 
adults without elav-GAL4, or adults expressing Htt-Q0 or Htt-Q128 with elav-GAL4 (Fig. 
2D).  Compared to controls, Htt-Q128/elav-GAL4 animals showed a dramatic reduction 
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FIGURE 2. Physiological and behavioral analysis of Htt-Q128-expressing 
transgenic Drosophila.  (A) Both UAS-Htt-Q128/GMR-GAL4 and pHS-Htt-Q128 exhibit 
reduced photoreceptor depolarization and loss of on/off transients (arrows), suggesting 
abolished synaptic transmission, in electroretinogram recordings.  (B) Extracellular 
recordings from the DLM flight muscles of Htt-Q0 and Htt-Q128 Drosophila are shown.  
A developmental heat-shock paradigm that induces Htt-Q128 expression results in 
abnormal seizure activity in the flight circuit at 38ºC.  For panels A and B, Drosophila 
were aged for 2-4 days at 25ºC.  (C) Quantitative analysis of wandering 3rd instar larval 
crawling behavior indicates that pan-neuronal expression of Htt-Q128 disrupts motor 
pattern generation, resulting in a significant decrease in locomotor speed.  30 larvae 
were analyzed for each genotype.  (D) Viability analysis of Drosophila maintained at 
25ºC indicates that pan-neuronal expression of Htt-Q128 with a second chromosome 
elav-GAL4 driver results in decreased lifespan compared to control strains.  Expression 
of Htt-Q128 with the stronger X-chromosome elav-GAL4 driver C155 leads to 100% 
pharate adult lethality. 
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in lifespan, with a decrease in T50 (age at which 50% of the culture has died) of 70%, 
indicating a highly significant effect of Htt-Q128 expression on lifespan in Drosophila 
(Fig. 2D). 
 
Altered gene expression in Drosophila expressing mutant Htt 
Microarray analysis has been used to identify mutant Htt-mediated changes in 
expression profile in several models of HD (Chan et al., 2002; Hodges et al., 2006; Luthi-
Carter et al., 2002a).  To characterize gene expression changes in our Drosophila HD 
model, expression profiling was performed with Affymetrix® high-density oligonucleotide 
GeneChip® arrays containing representative sequences for most of the 14,000 genes 
encoded by the Drosophila genome.  RNA was isolated from Drosophila head extracts 
from control strains or strains expressing Htt-Q0 or Htt-Q128 with the pan-neuronal elav-
GAL4 driver.  Two distinct stages were chosen for analysis: RNA was isolated at 3-4 
days post-eclosion, before the onset of a noticeable behavioral phenotype, and at 9-11 
days post-eclosion, when a severe behavioral phenotype was observed but just before a 
dramatic decrease in viability.  A total of 12 independent microarrays were analyzed (two 
each of RNA from 3-4 day-old control, Htt-Q0-, and Htt-Q128-expressing flies, and two 
each of RNA from 9-11 day-old control, Htt-Q0-, and Htt-Q128-expressing flies) for a 
total of eight pairwise comparisons between expression profiles from Htt-Q128-
expressing flies and Htt-Q0-expressing flies or control flies for both the 3-4 day set and 
the 9-11 day set.  Gene changes were called based upon the stringency criteria that 
differential regulation must be reported by Affymetrix® software for at least 75%, or 
twelve, of the sixteen pairwise comparisons for microarrays from both the 3-4 day set 
and the 9-11 day set.  In addition, the fold change in gene expression was required to be 
greater than or equal to 1.5 with a statistical significance of p<0.05.  Under these criteria, 
34 genes were found to be upregulated and 29 were downregulated in flies expressing 
mutant Htt as compared to control flies and flies expressing normal Htt.  In contrast, only 
7 genes were observed to be differentially regulated between normal Htt-expressing 
lines and control lines, indicating that expression of mutant Htt induced a significant 
change in gene transcription in Drosophila.   
Upregulated or downregulated genes were subjected to BLAST analysis in order 
to identify sequence and domain similarities to known proteins, and were categorized 
according to known or putative function (Tables 1 and 2).  While behavioral dysfunction 
is mild in Htt-Q128-expressing animals at 3-4 days post-eclosion, a robust 
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downregulation of eye-specific transcripts was observed, indicating significant 
degeneration of photoreceptors before the onset of behavioral defects.  In addition, a 
strong decrease in expression was seen for two metabolic genes, Sorbitol dehyrogenase 
1 and CG14576 (a UDP glucose 4-epimerase), at 3-4 days, and became more 
pronounced at 9-11 days, suggesting potential progressive metabolic defects in mutant 
Htt-expressing animals.  Surprisingly, few other categories of genes were shown to be 
downregulated, perhaps due to the stringency of the statistical criteria.  Upregulated 
categories included a number of immune response genes, which may indicate a strong 
immune response to the transgenic mutant Htt protein, and a small number of metabolic 
genes.  A robust increase in expression was seen for chaperone genes, especially 
CG6489, a Hsp70 homologue.  
 In summary, microarray analysis of mutant Htt-expressing flies reveals a 
neurodegenerative response early in disease progression before the appearance of 
obvious behavioral defects.  Upregulation of immune genes and chaperones provides 
evidence for a cellular stress response mounted specifically against the mutant protein, 
while changes in expression patterns for genes involved in metabolism suggest potential 
metabolic dysfunction.  Future studies may relax stringency criteria in order to identify 
genes that undergo more subtle changes in expression level, or may compare 
expression levels between control and experimental lines for candidate genes believed 
to undergo transcriptional dysregulation in HD. 
 
The 548 aa N-terminal fragment of mutant Htt forms cytoplasmic aggregates in 
neuronal and non-neuronal cells in Drosophila 
A hallmark of HD is the formation of Htt-immunopositive intracellular aggregates 
in neurons.  To determine whether intracellular aggregates are formed in transgenic Htt 
Drosophila, both Htt-Q128 and Htt-Q0 strains were crossed to flies containing C155 
elav-GAL4 to direct expression of Htt within the nervous system.  Htt-immunopositive 
staining was visualized in both central and peripheral neurons of dissected 3rd instar 
larvae.  While Htt staining remained diffuse throughout the cytoplasm of neurons in 
Drosophila expressing Htt-Q0 (Fig. 3A), distinct accumulations, or aggregates, of Htt 
were observed in the cytoplasm and processes of neurons in lines expressing Htt-Q128 
(Fig. 3B).  It is unclear whether the accumulations seen in our Drosophila model are 
structurally identical to the aggregates found in HD; however, the term “aggregate” is 
used here to describe microscopically visible accumulations of Htt protein.  Contrary to  
 86 
 87
 88 
 89
FIGURE 3. Cytoplasmic aggregation of Htt-Q128 in neuronal and non-neuronal 
tissues.  (A) Immunocytochemical detection of Htt (red) and HRP (green) in multi-
dendritic neurons of Htt-Q0-expressing 3rd instar larvae.  Htt-Q0 is found diffusely 
throughout the cytoplasm.  (B) Immunocytochemical detection of Htt (red) and HRP 
(green) in multi-dendritic neurons of Htt-Q128-expressing 3rd instar larvae.  Unlike Htt-
Q0, Htt-Q128 is found in cytoplasmic aggregates throughout the cell body and neurites.  
(C-H) Expression of UAS-Htt-Q128 (red) and UAS-GFP-nls (green) by tubP-GAL4 in the 
CNS (C), gut (D), salivary gland (E), trachea (F), muscle (G) and epidermis (H) of 3rd 
instar larvae.  In all cases, cytoplasmic aggregates are observed.  However, muscle and 
epidermis form far fewer aggregates than other tissues.  In polarized cells like the gut, 
basolateral transport of Htt aggregates is observed, with a complete absence of 
aggregates in the apical domain.  The nucleus is indicated by N, and Htt aggregates are 
highlighted with arrows.  (I) Immunocytochemical detection of Htt-Q128 (red) and HRP 
(green) in Drosophila embryos.  High levels of Htt are visible in the embryonic CNS and 
PNS, but few aggregates are observed in comparison to the 3rd instar larval stage (B), 
indicating that aggregate-formation is time-dependent. 
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what has been observed in several exon 1 HD models, we found no evidence for nuclear 
aggregate localization.  To verify that Htt aggregation is based on the length of the 
polyglutamine tract and not on protein concentration, Htt levels were quantified for 
several Htt-Q0 and Htt-Q128 transgenic lines crossed to elav-GAL4.  Levels of Htt 
protein were generally higher in Htt-Q128 lines than in Htt-Q0 lines, likely due to 
sequestration of the mutant protein into stable aggregates.  However, low-expressing 
Htt-Q128 lines that produced transgenic protein at a level comparable to that in Htt-Q0 
strains still exhibited aggregates, while Htt-Q0 lines did not (data not shown), indicating 
that polyglutamine tract expansion and not protein concentration alone is necessary for 
the formation of aggregates.  Aggregate formation was also time-dependent.  Although 
Htt levels were visibly high in the central and peripheral nervous system of Htt-
Q128/elav-GAL4 embryos, the protein remained largely diffuse in the cytoplasm with 
rare occurrence of aggregates (Fig. 3I).  By the 3rd instar larval stage, essentially all Htt 
was observed in aggregates, with relatively little non-aggregate staining (Fig. 3B).  We 
conclude that Htt-Q128 forms cytoplasmic neuronal aggregates in a time-dependent 
manner. 
Although the causative proteins for many of the polyglutamine repeat diseases 
are expressed ubiquitously, aggregate formation and cell death occur in subsets of 
neurons that differ between the diseases.  A central question in polyglutamine disease 
research is why certain cell types are affected in each disorder while others are spared, 
and why neurons are affected in every case.  To examine the effect of cellular context on 
aggregate formation, the Htt-Q128 protein was expressed in different tissues using the 
tubP-GAL4 driver.  We generated transgenic lines containing both the UAS-Htt-Q128 
construct and UAS-GFP fused to a nuclear localization signal, allowing for co-
visualization of Htt-immunopositive aggregates and GFP-stained cell nuclei in 
expressing cells. Immunocytochemical analysis demonstrated the formation of 
cytoplasmic aggregates in both neuronal and non-neuronal tissues, including CNS 
neurons (Fig. 3C), gut (Fig. 3D), salivary glands (Fig. 3E), and trachea (Fig. 3F).  
Interestingly, Htt aggregates were differentially distributed in polarized cells such as the 
gut, with transport of Htt aggregates to the basolateral domain and exclusion from the 
apical surface (Fig. 3D).  Similar aggregate transport was found in neurons (see below), 
indicating that Htt undergoes a cytoskeletal association that allows for directed transport.  
This suggests that the mutant protein may partially retain the ability of normal huntingtin 
to interact with microtubules and undergo transport (Block-Galarza et al., 1997).  Also 
 91
noteworthy is the fact that the Htt-Q128 protein was found in a more diffuse, non-
aggregated state in certain cell types, including muscle and epidermis (Fig. 3G & H), 
suggesting that some tissues may be more resistant to polyglutamine-mediated protein 
aggregation.  In all cell types where aggregate formation occurred, only cytoplasmic 
aggregates (as opposed to nuclear aggregates) were observed, suggesting unique 
differences between the larger Htt fragments used in our study compared to smaller Htt 
fragments that form nuclear aggregates in other HD models. 
 
The protein context of the polyglutamine repeat controls aggregate formation and 
localization 
Although the polyglutamine repeat diseases all result from CAG repeat 
expansion in the causative gene, the pattern of neurodegeneration and behavioral 
dysfunction is distinct for each disorder, indicating that the protein context for expanded 
polyglutamine tracts is critical to disease manifestation.  The protein context may 
determine aggregation potential, subcellular localization, toxicity, and potential binding 
partners.  To examine the importance of protein context in the subcellular localization of 
polyglutamine-containing proteins, immunocytochemical analysis was performed on 
larvae expressing either an expanded polyglutamine tract alone (Q127) (Kazemi-
Esfarjani and Benzer, 2000), the mutant polyglutamine protein responsible for Machado 
Joseph disease (SCA3-Q78) (Warrick et al., 1998) or an expanded polyglutamine tract 
(Q108) previously engineered into the non-pathogenic dishevelled gene (Marsh et al., 
2000).  In contrast to the cytoplasmic localization of Htt aggregates (Fig. 4A), both Q127 
and SCA3-Q78 aggregates localized exclusively to the nucleus (Fig. 4B & C). Very few 
Dishevelled-immunopositive aggregates were observed (Fig. 4D), and the protein was 
present diffusely in the cytoplasm.  These results demonstrate that the protein context in 
which the polyglutamine tract is found exquisitely controls both aggregate localization 
and aggregate formation.   
To test whether Htt-Q128 can interact and co-aggregate with other polyglutamine 
repeat proteins, we generated double transgenic Htt-Q128;Q127 and Htt-Q128;SCA3-
Q78 strains expressing both transgenes.  When the Htt-Q128 and Q127 proteins were 
co-expressed, both central and peripheral neurons showed localization of Htt-Q128 
aggregates to the cytoplasm while Q127 aggregates were restricted to the nucleus (Fig. 
4E & H).  Likewise, in strains expressing Htt-Q128 and SCA3-Q78, aggregates were 
segregated independently in the cytoplasm and nucleus (respectively) of both neuronal 
 92 
 93
FIGURE 4. Protein context is important for polyglutamine-mediated aggregation 
and aggregate localization.  (A-D) Immunolocalization of aggregates in 3rd instar 
larvae expressing Htt-Q128 (A), Q127 (B), SCA3-Q78 (C) and Dsh-Q108 (D) in multi-
dendritic neurons with the C155 elav-GAL4 driver.  Htt-Q128 aggregates are exclusive to 
the cytoplasm, while Q127 and SCA3-Q78 aggregates are found only in the nucleus.  
Dsh-Q108 is mostly diffuse in the cytoplasm, with few aggregates visible.  The nucleus is 
represented by N.  (E, F) Double transgenic 3rd instar larvae expressing Htt-Q128 and 
Q127 (E) or Htt-Q128 and SCA3-Q78 (F) with the elav-GAL4 driver were dissected and 
immunostained for Htt (red) or SCA3/Q127 (green).  Multi-dendritic sensory neurons 
were identified as in panels A-D, and assayed for aggregate colocalization.  No 
colocalization of aggregates is observed, indicating distinct nuclear and cytoplasmic 
aggregation pathways.  Similar results are observed in the CNS (H) and in non-neuronal 
tissues such as the salivary glands (G).  (I) In contrast, in double transgenic larvae 
expressing Htt-Q128 and Dsh-Q108 with elav-GAL4, Htt-Q128 (red) is able to 
completely sequester Dsh-Q108 (green) into aggregates as indicated by yellow 
colocalization in the merged panel. 
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(Fig 4F) and non-neuronal (Fig. 4G) cells.  These results suggest that the trafficking and 
aggregation of nuclear and cytoplasmic aggregates are independently regulated. 
To determine whether Htt-Q128 might interact with cytoplasmic proteins 
containing an expanded polyglutamine tract, double transgenic strains were made 
containing Htt-Q128 and Dishevelled-Q108 (Dsh-Q108).  As demonstrated above (Fig. 
4D), Dsh-Q108 formed few aggregates when expressed alone; however, when co-
expressed with Htt-Q128, the subcellular distribution of Dsh-Q108 shifted from a diffuse 
cytoplasmic pattern to a complete sequestration into aggregates that colocalized with 
Htt-Q128 (Fig. 4I).  Similar sequestration of endogenous cytoplasmic proteins by Htt 
aggregates might be predicted to play an important role in disease pathology.  
 
Mutant Htt aggregates block axonal transport 
As described above (Fig. 3D), Htt-Q128 forms cytoplasmic aggregates that are 
associated with cytoskeletal transport systems.  It is important to define if and how 
transport of aggregates contributes to disease pathology. When Htt-Q128 was 
expressed with the eye-specific driver GMR-GAL4, Htt aggregates were abundantly 
transported along axons entering the CNS of the developing visual system and 
accumulated in pathfinding photoreceptor growth cones (Fig. 5A & B).  Similarly, when 
Htt-Q128 was expressed with the C155 driver, aggregates were transported in larval 
motor axons and accumulated at presynaptic neuromuscular junction terminals (Fig. 5D 
& F).  No aggregates were observed in axons from animals expressing Htt-Q0 (Fig. 5C & 
E).  Axonal transport of aggregates was not observed in transgenic animals that produce 
exclusively nuclear aggregates (Q127 and SCA3-Q78) (Fig. 5G), suggesting that axonal 
and synaptic defects that may occur downstream of cytoplasmic aggregate formation are 
likely to be specific to HD.  Additionally, no Dsh-Q108 aggregates were observed in axon 
bundles (Fig. 5H).  However, when Dsh-Q108 was co-expressed with Htt-Q128, Dsh-
Q108 protein trapped by Htt-Q128 was also transported along axons (Fig. 5I).  Similar 
recruitment of endogenous cytoplasmic polyQ proteins may sequester them away from 
their natural cellular locations and contribute to neuronal dysfunction. 
In observing axonal aggregates in Htt-Q128 expressing animals, it was noted 
that the diameter of Htt aggregate accumulations often appeared to exceed that of 
normal larval axons.  This suggested that large Htt aggregates might physically block 
axonal transport, as would be manifested by axonal swellings at the sites of such 
blockages.  We tested this hypothesis in Htt-Q128-expressing animals by observing the 
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localization of synaptotagmin I, a synaptic vesicle protein exclusively localized to 
synapses in Drosophila.  Normal transport of the synaptotagmin protein along axons is 
below the threshold for immunocytochemical detection (Littleton et al., 1993).  This 
standard pattern of synaptotagmin trafficking, as observed in Htt-Q0 expressing animals 
(Fig. 5J), is abruptly altered in Htt-Q128-expressing Drosophila.  Instead of the normal 
diffuse localization along axonal tracts, synaptotagmin became concentrated at specific 
points along axons that corresponded to large areas of Htt-immunopositive aggregate 
accumulation, suggesting sites of axonal blockage (Fig. 5K).  These synaptotagmin-rich 
areas of Htt aggregate accumulation were quantified in 100 μm segments along 
peripheral nerves and were observed at a density of 6.1 + 2.6 sites per 100 μM.  In 
contrast, synaptotagmin-immunopositive accumulations alone without Htt aggregate 
colocalization were only observed at a density of 1.3 + 0.9 per 100 μM.  The average 
diameter of Htt-Q128 aggregate accumulations at putative axonal blockage sites was 2.4 
+ 0.6 μM.  Aggregate accumulations smaller than 2.0 μM rarely resulted in colocalized 
synaptogtagmin concentration.  These results indicate that axonal segments may be 
obstructed by a concentration of Htt aggregates that exceeds a critical threshold, leading 
to a specific block in axonal transport at these sites.  Over time, the cumulative blockage 
of axons and synaptic terminals in post-mitotic neurons is likely to contribute to the 
progressive physiological defects and neuronal dysfunction we have documented in Htt-
Q128 expressing Drosophila, as well as to late-onset neurodegeneration in HD patients. 
 
Electrophysiological analysis of synaptic function in Drosophila expressing 
mutant Htt 
Blockage of axons and synaptic terminals by aggregates of mutant Htt may 
prevent proper localization of synaptic components, leading to synaptic pathology.  
Indeed, studies have shown defects in neurotransmitter release in transgenic HD mice 
(Nicniocaill et al., 2001; Usdin et al., 1999), indicating that expression of mutant Htt 
induces dysfunction at the synapse.  To characterize the physiological consequences of 
mutant Htt expression at the 3rd instar larval neuromuscular junction (NMJ) of transgenic 
Drosophila, intracellular recordings were performed on control larvae and larvae 
expressing Htt-Q0 or Htt-Q128 with the pan-neuronal C155 elav-GAL driver.  Analysis of 
basal synaptic transmission, short-term synaptic facilitation, and spontaneous vesicle 
fusion events was performed to quantify mutant Htt-induced alterations in synaptic 
function.
 96 
 97
FIGURE 5. Htt-Q128 aggregates block axonal transport.  (A, B) Expression of Htt-
Q128 by GMR-GAL4 results in axonal transport of Htt aggregates (arrows) in the 
developing visual system.  (C, D) Expression of Htt-Q128 (D), but not Htt-Q0 (C), by 
elav-GAL4 results in axonal transport and synaptic accumulation of Htt aggregates at 
neuromuscular junctions in 3rd instar larvae.  Axonal transport of aggregates is 
abundant in Htt-Q128-expressing 3rd instar larvae (F), but absent in animals expressing 
Htt-Q0 (E), Q127 (G) or Dsh-Q108 (H).  Nerves are stained green by anti-HRP, and 
polyglutamine proteins are visualized in red.  (I) Consistent with the trapping of Dsh-
Q108 by Htt-Q128 aggregates in the cell bodies of multi-dendritic sensory neurons, Htt-
Q128 also traps and transports Dsh-Q108 in peripheral nerves.  (J, K) Expression of Htt-
Q128 (K), but not Htt-Q0 (J), results in an accumulation of the synaptic protein 
synaptotagmin I in sites of axonal swelling, colocalizing with large accumulations of Htt-
Q128 aggregates.  Synaptotagmin I is not trapped in Htt-Q128 aggregates, as indicated 
by the lack of protein colocalization in smaller Htt-Q128 aggregates, but rather 
concentrates specifically at sites where larger aggregate accumulations result in swollen 
axons, indicating blockage of axonal transport. 
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No change was seen in resting membrane potential between control and Htt-
Q128-expressing animals (Fig. 6A), suggesting that the resting status of postsynaptic 
muscle cells at the NMJ is not affected by presynaptic expression of mutant Htt.  To 
determine whether mutant Htt induces a change in basal synaptic transmission, evoked 
excitatory junctional potentials (EJPs) were recorded in the presence of low external 
Ca2+ (0.2 mM), allowing for sensitive detection of alterations in neurotransmitter release.  
No statistical differences were observed in EJP amplitude between control white flies, 
Htt-Q0-expressing flies, and Htt-Q128-expressing flies (Fig. 6B), indicating a lack of 
gross mutant Htt-induced defects in vesicle docking or fusion machinery. 
To detect potential defects in calcium handling at NMJ synapses of mutant Htt-
expressing animals, paired pulse-facilitation was performed.  Paired-pulse facilitation is 
used to measure short-term plasticity on a timescale of milliseconds, and is performed 
by evoking two action potentials within a set time interval under low calcium conditions.  
At close time intervals, residual intracellular Ca2+ from the first evoked potential will 
induce a larger second release event (Zucker and Regehr, 2002); alterations in cellular 
calcium management will thus manifest as changes in facilitation of the second evoked 
action potential.  No statistical changes in paired-pulse facilitation were observed 
between control and Htt-Q128-expressing lines (Fig. 6C), indicating a lack of observable 
defects in calcium buffering at the NMJ of transgenic 3rd instar larvae expressing mutant 
Htt. 
Miniature excitatory junctional potentials (mEJPs) were then analyzed to monitor 
defects in spontaneous synaptic vesicle fusion and vesicle neurotransmitter content.  
mEJP frequency was slightly increased in animals expressing Htt-Q128 (Fig. 7A), 
suggesting that spontaneous vesicle fusion may be altered in the presence of mutant 
Htt.  No change was observed in mEJP mean amplitude between control and Htt-Q128-
expressing animals (Fig. 7B), indicating that neurotransmitter content of individual 
vesicles is not altered; however, multiple spontaneous vesicle fusion events 
(simultaneous release from more than one vesicle) are increased in a subset of NMJ 
synapses from Htt-Q128-expressing animals, implying potential facilitation of 
spontaneous fusion in the presence of mutant Htt.   
Future studies will include further analysis of the subset of synapses producing 
irregular mEJPS; while no overall difference is observed in mean EJP amplitude or 
paired-pulse facilitation between control and mutant Htt-expressing lines, statistical 
analysis may reveal significant alterations in synaptic function that occur in only this 
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subset of synapses.  Studies may also be performed to visualize the synaptic 
morphology at these NMJs in comparison to NMJs in mutant Htt-expressing animals that 
show no evidence of synaptic dysfunction.  In addition, future work will include study of 
defects in vesicle endocytosis and recycling through stimulation under high calcium, high 
frequency conditions to quantitate changes in activity-dependent reduction in evoked 
currents over time.  Impairment of synaptic function in HD may contribute to neuronal 
pathology seen in the disease.  It will be of interest to determine if these pathological 
mechanisms can be modeled in Drosophila. 
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FIGURE 6. Basal synaptic transmission and paired pulse facilitation are 
unchanged in Drosophila expressing Htt-Q128.  (A) Average muscle resting 
potentials are unchanged at the NMJ of wandering 3rd instar larvae expressing Htt-Q128 
compared to Htt-Q0 or controls.  Error bars are SEM.  (B) Mean evoked EJP amplitudes 
recorded in 0.2 mM extracellular calcium for the indicated genotypes.  No change is 
seen in EJP amplitude for larvae expressing Htt-Q128 compared to Htt-Q0 or controls.  
Error bars are SEM.  (C) Quantification of paired-pulse facilitation for the indicated 
genotypes.  Recordings were performed in 0.2 mM extracellular calcium.  Facilitation of 
the second response is unaltered in Htt-Q128-expressing larvae compared to Htt-Q0 or 
controls.   
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FIGURE 7. mEJP frequency and multiple spontaneous fusion events are increased 
in Htt-Q128-expressing Drosophila.  (A) Frequency of mEJP events per 30 seconds 
recorded at the 3rd instar larval NMJ of control, Htt-Q0-expressing, or Htt-Q128-
expressing animals.  A slight increase in mEJP frequency is seen in larvae expressing 
Htt-Q128.  Error bars are SEM.  (B) Histogram of mEJP events recorded at the NMJ of 
control, Htt-Q0-expressing, or Htt-Q128-expressing 3rd instar larvae.  No change is seen 
in amplitude of individual mEJP events.  However, animals expressing Htt-Q128 exhibit 
a slight increase in multiple mEJP events.   
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Discussion 
 
Many neurodegenerative diseases, including Parkinson’s disease (Feany and 
Bender, 2000), Alzheimer’s disease (Wittmann et al., 2001), and spinocerebellar ataxia 
type 1 (Fernandez-Funez et al., 2000) and type 3 (Warrick et al., 1998) have been 
successfully modeled in Drosophila with replication of key neuropathological features of 
the human diseases, including late onset and progressive neurodegeneration.  
Development of such disease models may facilitate the identification of molecular 
pathways that lead to neurodegeneration in the corresponding human disorders.   
Several existing Drosophila models of HD (Muqit and Feany, 2002) target 
expression of the first exon of the mutant Htt protein to the fly retina, either through use 
of an eye-specific promoter (Jackson et al., 1998) or the GAL4/UAS system (Steffan et 
al., 2001).  In both HD models, expression of Htt with a pathogenic number of glutamine 
repeats results in nuclear accumulation of aggregates and progressive 
neurodegeneration of photoreceptor cells, suggesting a role for nuclear aggregates in 
disease pathology.  Indeed, nuclear aggregate-mediated impairment of transcription has 
become a favored hypothesis to explain polyglutamine-mediated neurodegeneration 
(Ross, 2002).  Drosophila HD models expressing Htt transgenes with a pan-neuronal 
GAL4 driver (Gunawardena et al., 2003) suggest that non-nuclear pathology associated 
with cytoplasmic and neuritic aggregates is likely to play an essential role in disease 
progression as well.  Given that Drosophila polyglutamine disease models with either 
nuclear-restricted (expanded polyQ alone, mutant SCA-3) or cytoplasm-restricted (Htt-
Q128) aggregates both exhibit neurodegeneration, it is likely that multiple pathways for 
polyglutamine-mediated dysfunction exist.  Indeed, we have been unable to rescue adult 
lethality in Htt-Q128-expressing Drosophila with any of the previously published genetic 
suppressors of Drosophila transgenic polyglutamine models (Chan et al., 2000; 
Fernandez-Funez et al., 2000; Kazantsev et al., 2002; Kazemi-Esfarjani and Benzer, 
2000).  These negative results likely reflect distinct modes of toxicity between nuclear 
and cytoplasmic aggregates, and suggest that preventing polyglutamine-mediated Htt 
toxicity may require more research into the role of non-nuclear aggregates.  
We have demonstrated a potential role for cytoplasmic and neuritic aggregates 
in the sequestration of cytoplasmic polyQ proteins and in the blockage of axonal 
transport.  Consistent with our hypothesis that Htt-Q128 expression causes 
neurodegeneration secondary to axonal transport impairment, several recent studies 
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have found that neurodegeneration is a primary consequence of axonal transport 
defects in non-polyglutamine diseases as well (Hafezparast et al., 2003; LaMonte et al., 
2002; Lee and Cleveland, 1994; Puls et al., 2003), including Alzheimer’s disease 
(Gunawardena and Goldstein, 2001).  In summary, our results indicate that cytoplasmic 
aggregate formation in HD sequesters endogenous polyglutamine proteins and blocks 
axonal transport, contributing to neuronal dysfunction and neurodegeneration. 
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Abstract 
 
To explore axonal transport defects in Huntington’s disease, we generated Drosophila 
transgenic strains expressing 588 aa N-terminal fragments of human huntingtin 
encoding pathogenic (HttQ138) or nonpathogenic (HttQ15) proteins tagged with mRFP 
and/or eGFP.  These transgenic lines allow in vivo imaging of Htt aggregation and 
trafficking in live Drosophila, providing a unique resource for tracking Htt in real time.  
Expression of pathogenic Htt proteins results in the formation of neuritic aggregates that 
are immobile and physically block axonal transport of various cargoes, including synaptic 
and dense core vesicles, clathrin-coated vesicles, endosomes, cytosolic proteins, and 
the normal Htt protein.  In addition, the number of mitochondria and dense core vesicles 
is reduced in axons of mutant Htt-expressing animals, suggesting a potential mutant Htt-
mediated disruption of interactions between specific transport cargoes and axonal 
transport machinery.   Our findings indicate that expression of mutant Htt may impair 
axonal transport through both aggregate-dependent and -independent means. 
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Introduction 
 
Huntington’s disease (HD) is one of nine known neurological disorders caused by 
a polyglutamine (polyQ) repeat expansion.  The disease is characterized by 
neurodegeneration and formation of neuronal intracellular inclusions primarily in the 
striatum and cortex, leading to personality changes, motor impairment, and dementia 
(Vonsattel et al., 1985).  The causative mutation in HD is expansion of a polyQ tract in 
exon 1 of the gene encoding huntingtin (Htt) (HDCRG, 1993), a 348 kDa protein 
hypothesized to be involved in vesicular transport (Block-Galarza et al., 1997; DiFiglia et 
al., 1995; Gauthier et al., 2004).  Expansion of the polyQ repeat in Htt is thought to 
promote abnormal protein conformation(s) that lead to the formation of aggregates and 
are central to disease pathogenesis (Persichetti et al., 1999; Scherzinger et al., 1997).  
However, the molecular mechanisms that underlie the neurodegenerative process 
remain to be defined. 
While several studies suggest that intranuclear aggregates are the primary cause 
of HD (Becher et al., 1998; Davies et al., 1997), recent evidence points to a pathological 
role for the mutant protein in the cytoplasm and neurites (Li et al., 1999a; Sapp et al., 
1999) and possibly at the synapse (Li et al., 2003c; Usdin et al., 1999).  In particular, 
recent studies indicate that disruption of Htt function may impair axonal transport, either 
through toxic effects of the mutant protein (Gunawardena et al., 2003; Lee et al., 2004; 
Szebenyi et al., 2003; Trushina et al., 2004) or through loss of the normal protein 
(Gunawardena et al., 2003; Trushina et al., 2004).  Axonal transport is essential for 
delivery of proteins from the neuronal cell body to the synapse, and to convey retrograde 
signals from the synapse to the cell body.  In addition to Huntingon’s disease, 
impairment of axonal transport has been implicated in other late-onset 
neurodegenerative disorders including amyotrophic lateral sclerosis (Kieran et al., 2005; 
Williamson and Cleveland, 1999), spinal bulbar muscular atrophy (Piccioni et al., 2002), 
Parkinson’s disease (Saha et al., 2004), and Alzheimer’s disease (Chee et al., 2006; 
Praprotnik et al., 1996). 
Expression of the  mutant Htt protein has been shown to disrupt axonal transport 
of exogenous markers (Li et al., 2001), synaptic vesicles (Lee et al., 2004), neurotrophic 
factors (Gauthier et al, 2004), and organelles (Chang et al., 2006).  In particular, 
impaired axonal transport may lead to defects in trafficking and distribution of 
mitochondria.  Proper mitochondrial distribution is necessary for calcium buffering, 
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sequestration of apoptotic signals, and production of ATP in areas of high metabolic 
need; defects in trafficking of mitochondria can both decrease the number of healthy 
mitochondria in areas of need and increase the number of old or damaged mitochondria 
that can cause neuronal damage.  Recent studies suggest that defective mitochondrial 
transport may be a factor in HD pathology.  A 50% decrease in wild-type Htt results in a 
decrease in the motility of mitochondria (Trushina et al., 2004).  Additionally, in flies 
lacking Milton, the Drosophila homologue of HAP1 (a known Htt interactor), mitochondria 
are prevented from entering the axon and remain in the cell body (Stowers et al., 2002), 
further suggesting a link between Htt function and mitochondrial transport in the axon.  
Expansion of the polyQ repeat in Htt reduces mitochondrial movement in HD cortical 
neurons (Chang et al., 2006) and in striatal neurons from transgenic HD mice (Trushina 
et al., 2004), indicating that mutant Htt may impair transport of mitochondria in HD.  
Defects in mitochondrial transport, and resulting mitochondrial insufficiency and 
dysfunction, may contribute to the excitotoxicity, oxidative damage, and neuronal cell 
death observed in Huntington’s disease. 
To characterize axonal transport defects in Huntington’s disease, we generated 
transgenic Drosophila that express 588 aa N-terminal fragments of the human Htt gene 
with either a pathogenic polyQ tract of 138 repeats (HttQ138) or a non-pathogenic tract 
of 15 repeats (HttQ15).  These fragments were fused to mRFP or eGFP at the N-
terminus, or to eGFP at the N-terminus and mRFP at the C-terminus, to allow for in vivo 
imaging.  We also generated a transgenic strain expressing exon 1 of the human Htt 
protein with a 96Q repeat, fused to GFP at the C-terminus (HttQ96-GFP).  Our findings 
indicate that expression of either the 588 aa or exon 1 mutant Htt fragment leads to the 
formation of non-nuclear aggregates in both neuronal and non-neuronal cell types, and 
can induce cellular dysfunction.  In neurons, Htt-immunopositive aggregates occur in 
both the axon and dendrites, and larger aggregates are immobile during development.  
These aggregates physically block the axon, capturing axonal transport cargoes such as 
synaptic and dense core vesicles, clathrin-coated vesicles, endosomes, and cytosolic 
proteins, as well as the normal Htt protein.  A subset of mitochondria colocalize and are 
transported with the normal Htt protein.  However, this association is reduced between 
mitochondria and mutant Htt, suggesting that impairment of the normal role of Htt in 
mitochondrial transport may contribute to disease pathogenesis.  Defects in axonal 
transport and corresponding neurodegeneration in post-mitotic neurons may underlie 
many symptoms of HD pathology.  In Drosophila models of HD, these axonal transport 
 115
defects arise from both a physical blockage in transport secondary to neuritic aggregate 
formation, and a non-aggregate-dependent reduction in axonal cargo, including 
mitochondria. 
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Materials and Methods 
 
Drosophila Genetics and Generation of Htt Constructs 
Drosophila melanogaster were maintained on standard medium at 25oC.  cDNAs 
for mRFP-HttQ15, mRFP-HttQ138, eGFP-HttQ15, eGFP-HttQ138 were subcloned into 
the EcoRI (blunt end ligation) and KpnI sites of the pUAST expression vector.  cDNA for 
eGFP-HttQ138-mRFP was subcloned into the XbaI site of the pUAST vector.  cDNA for 
HttQ96-GFP was kindly provided by David Housman (Center for Cancer Research, MIT) 
and was subcloned into the KpnI and XbaI sites of the pUAST vector.  Microinjection of 
mRFP-HttQ15, mRFP-HttQ138, eGFP-HttQ15, eGFP-HttQ138, and eGFP-HttQ138-
mRFP constructs into Drosophila embryos was performed by the Duke University Model 
Systems Genomics Group, while microinjection of HttQ96-GFP was performed by 
Genetic Services, Inc. 
 
S2 Cell Transfection and Analysis   
cDNAs for mRFP-HttQ15 and mRFP-HttQ138 were subcloned into the BamH1 
and EcoRI (blunt end ligation) sites of the pSR11 vector.  To generate constructs 
expressing mRFP-HttQ15-eGFP and mRFP-HttQ138-eGFP, mRFP-HttQ15 and mRFP-
HttQ138 cDNAs were PCR amplified with a forward primer containing an EcoRI 
restriction site and a reverse primer containing a 3’ Sal I site.  The added restriction sites 
were then used to subclone the PCR products into the pPL17 vector.   Constructs were 
transfected with 50 μL cytofectene (BioRad) into Drosophila S2 cells using the BioRad 
Liposome Mediated Transfection Protocol.  4 μG of construct DNA were used per 5 mL 
S2 cell culture for single transfections while 4 μG of each construct were used for double 
transfections.  After 72 hours, 20 μL cell suspensions were fixed with 3.7% formaldehyde 
in 1 x PBT, then mounted on slides with 50% glycerol in 1 x PBS.  Visualization of slides 
was performed on a Pascal confocal microscope (Zeiss). 
 
Western Blot Analysis  
For the HttQ96-GFP Western blot, Drosophila were frozen in liquid nitrogen and 
vortexed.  20 heads for each indicated genotype were isolated and homogenized in 
sample buffer, and proteins were separated on 10% SDS-PAGE gels.  The gels were 
immunoblotted with rabbit anti-GFP sc8334 (Santa Cruz Biotechnology) at 1:1,000, and 
immunoreactive bands were visualized by using ECL (Pierce).  For the eGFP-Htt and 
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mRFP-Htt Western blot, 5 larvae for each indicated genotype were homogenized in 
sample buffer and proteins were separated on 10% SDS-PAGE gels.  The gels were 
immunoblotted with mouse anti-Htt MAb2166 (Chemicon) at 1:1,000, and 
immunoreactive bands were visualized by using ECL (Pierce). 
 
Adult Viability Analysis   
Drosophila viability assays were performed on white/C155, HttQ96-GFP/C155, 
mRFP-HttQ15 /C155, mRFP-HttQ138/C155, and mRFP-HttQ138 B/C155 flies by daily 
quantification of lethality for 100 males and 100 females of each genotype.  Flies were 
aged at 25oC, with 20 flies per food vial, and were transferred every 2-3 days. 
 
Morphological Analysis  
Wandering 3rd instar larvae reared at 25oC were dissected as described 
(Rieckhof et al., 2003).  For Alexa Fluor® 488 phalloidin-staining, larvae were fixed for 
15 minutes in 4% formaldehyde in HL3.1 solution (Stewart et al., 1994), washed for 15 
minutes in phosphate-buffered saline (PBS), and stained for 15 minutes with Alexa 
Fluor® 488 phalloidin (Invitrogen) at 1:500.  Immunostaining was performed on larvae 
fixed for 40 minutes in 4% formaldehyde solution in HL3.1 solution at room temperature.  
Primary antibody against Drosophila complexin (Littleton Lab, unpublished) was used at 
1:500 and visualized with Cy2-conjugated secondary antibody (Jackson Labs).  
Visualization and quantification were performed on a Pascal confocal microscope 
(Zeiss). 
 
Glue Secretion Assay 
Pupae reared at 25oC were isolated shortly after pupariation and adhered to 
glass slides with ventral sides facing up using double-sided tape.  For salivary gland 
analysis, salivary glands were dissected from wandering 3rd instar larvae and mounted 
in 70% glycerol in phosphate-buffered saline (PBS) on glass slides.  Visualization and 
quantification were performed on a Pascal confocal microscope (Zeiss). 
 
Axonal Transport Rate Analysis  
Time-lapse imaging of GFP and RFP particle movement in Drosophila motor 
axons was performed as described (Horiuchi et al, 2005).  NIH Image version 1.62b7 
was used with an object tracking macro based on software designed by Kurt Anderson 
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and Rob Cross (http://mc11.mcri.ac.uk/motorhome.html) to mark the positions of 
individual RFP or GFP particles.  Anterograde movements were given a positive 
designation and retrograde displacements were given a negative designation.  To 
describe transport behavior, particle motility was modeled as a three-state system 
consisting of plus-end and minus-end runs, based on periods of uninterrupted motion, or 
pauses, based on lack of motion.  Mean velocities, durations, and lengths were 
calculated for plus- and minus-end runs, as well as mean duration for pauses.  The “duty 
cycles” of transport represent the percentage of time spent by particles in each of the 
three states.  Graphing, modeling, and statistical analysis of organelle tracking data were 
done using SPSS Base 10.0 (SPSS Inc., Chicago, IL) and Microsoft Excel. 
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Results 
 
The 588 aa N-terminal fragment of mutant human Htt reduces Drosophila lifespan 
To explore axonal transport defects in Huntington’s disease, we generated 
transgenic Drosophila that express 588 aa N-terminal fragments of human Htt gene with 
either a pathogenic polyQ tract of 138 repeats (HttQ138) or a non-pathogenic tract of 15 
repeats (HttQ15).  While several models of HD have focused on expression of the 
polyglutamine-containing first exon of Htt alone, the 588 amino acid fragment is 
truncated near a number of well-characterized sites of caspase cleavage, thought to be 
a crucial step in the generation of aggregate-forming Htt fragments (Kim et al., 2001; 
Wellington et al., 2002).  Additionally, many sites of protein interaction that are lost in 
exon 1 constructs are conserved in the 588 aa fragment, including a region of well-
conserved HEAT repeats known to be involved in Htt binding to interaction partners such 
as HIP1, HAP1, and HIP14 (Harjes and Wanker, 2003).  The 588 aa fragment also 
encompasses the highest stretch of homology between the Drosophila and human Htt 
proteins (Li et al., 1999b), providing a more accurate representation of the in vivo Htt 
protein context for the polyglutamine tract.  The fragments were fluorescently tagged 
with mRFP or eGFP at the N-terminus, or tagged at both ends with eGFP at the N-
terminus and mRFP at the C-terminus.  For comparison, we also created a transgenic 
strain expressing exon 1 (81 aa) of the human Htt protein with a pathogenic 96Q repeat, 
fused to GFP at the C-terminus (HttQ96-GFP).  All constructs are expressed using the 
UAS-GAL4 system, which allows for temporal and tissue-specific control of transgene 
expression.  These transgenic lines allow in vivo imaging of Htt aggregation and 
trafficking in live Drosophila, providing a unique resource for tracking Htt in real time 
(Fig. 1A). 
To confirm transgene expression, strains were crossed to the neuronal GAL4 
driver C155 elav-GAL4, and Htt expression in offspring was assessed through Western 
blot analysis with anti-human Htt antibodies (Fig. 1B).  No Htt expression is detected in 
control lines crossed to the neuronal GAL4 driver, while mRFP-Htt, eGFP-Htt, and 
HttQ96-GFP lines all demonstrate abundant Htt expression.  As expected, the product 
detected in HttQ15 strains lacking the expanded polyglutamine tract is smaller than that 
in HttQ138 or HttQ96 strains.   
Pan-neuronal expression of mRFP-HttQ138 with the C155 elav-GAL4 driver 
causes pharate adult lethality with less than 1% viable adult escapers.  Expression of 
 120
 121
FIGURE 1. Generation of a Drosophila transgenic model of HD.  (A) The N-terminal 
fragments of human Htt used for transgenic construction.  Polyglutamine tracts (Q) and 
fluorescent tags (mRFP, eGFP) are indicated.  The full-sized Htt protein is depicted for 
comparison.  (B) Expression of Htt in control, mRFP-Htt, eGFP-Htt, and HttQ96-GFP 
strains with transgene expression driven by the C155 elav-GAL4 driver.  Western 
blotting was performed with an antibody to the N-terminus of human Htt (mRFP-Htt and 
eGFP-Htt blot) or an antibody to GFP (HttQ96-GFP blot).  (C) Reduced viability of 
transgenic strains expressing mutant Htt.  T50 is decreased by over 70% in strains 
expressing mRFP-HttQ138, 30% in strains expressing mRFP-HttQ138B (a lower 
expression strain), and 50% in strains expressing HttQ96-GFP, in comparison to 
controls.   
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mutant Htt with a weaker elav-GAL4 driver results in viable adults that appear 
behaviorally normal at the time of eclosion.  However, several days after eclosion, 
mRFP-HttQ138-expressing flies begin to exhibit motor coordination defects and 
abnormal grooming behaviors, worsening with age and resulting in premature death.  
Similar defects occur at a later timepoint in a separate mRFP-HttQ138 insertion line 
expressing mutant Htt at a lower level, as well as in flies expressing the mutant HttQ96-
GFP exon 1 protein.  These behaviors are not observed in mRFP-HttQ15-expressing 
flies or control flies.  To quantify the reduction in viability of mutant Htt-expressing flies, 
lifespan curves were generated for control adults and adults expressing mRFP-HttQ15, 
mRFP-HttQ138, mRFP-HttQ138B (a line expressing a lower level of mRFP-HttQ138), or 
HttQ96-GFP.  The T50 (age at which 50% of the culture has died) for mRFP-HttQ138 
lines is dramatically decreased by over 70% in comparison to controls.  A lower 
expression strain (mRFP-HttQ138B) shows a 30% decrease in T50, indicating that 
viability is inversely correlated with the level of expression of the mutant protein.  
HttQ96-GFP lines also demonstrate a decrease in T50 of 50%, suggesting that 
expression of the expanded polyQ-containing first exon of Htt is also toxic (Fig. 1C).  
Decreases in T50 for all lines expressing fragments of the mutant Htt protein, but not the 
normal protein, indicate that expression of mutant Htt significantly reduces lifespan in 
Drosophila.   
 
Mutant Htt forms cytoplasmic aggregates in neuronal and non-neuronal cells in 
vivo   
A hallmark of HD is the formation of intracellular aggregates immunopositive for 
the mutant Htt protein.  To determine the effect of transgene expression at the cellular 
level, Drosophila S2 cells were transiently transfected with the mRFP-HttQ15 or mRFP-
HttQ138 constructs and imaged through confocal microscopy.  While mRFP-HttQ15 
demonstrated diffuse cytoplasmic localization, mRFP-HttQ138 formed large, distinct 
cytoplasmic aggregates (Fig. 2A).   
To assess whether intracellular aggregates are also formed in vivo by the 
transgenic proteins, mRFP-Htt strains were crossed to lines expressing the pan-
neuronal C155 elav-GAL4 driver, and 3rd instar larval offspring were imaged using 
confocal microscopy.  As observed in S2 cells, mRFP-HttQ15 remained diffuse 
throughout the cytoplasm and neurites of neurons in both the CNS (Fig. 2B) and PNS 
(Fig. 2D).  In contrast, distinct Htt aggregates were observed throughout the cytoplasm 
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and neurites in lines expressing mRFP-HttQ138 (Fig. 2C & E).  mRFP-HttQ15 is also 
diffusely localized in the cytoplasm of non-neuronal cells such as epidermis (Fig. 2E) 
and salivary glands (Fig. 2G), while mRFP-HttQ138 forms cytoplasmic aggregates (Fig. 
2F & H).  Nuclear aggregates were not observed in any cell types.   
 
Mutant Htt causes defects in salivary gland glue secretion in Drosophila 
To determine whether the abundant presence of Htt aggregates in larval salivary 
glands (Fig. 2G) causes cellular dysfunction, salivary gland secretion of GFP-tagged 
glue was compared between control animals and animals expressing mRFP-HttQ138.  
During normal pupariation, Drosophila pupae secrete a glue-like substance from the 
salivary glands to attach the pupal case to a surface (Fig. 3A).  While glue secretion is 
evident in both control and mRFP-HttQ15-expressing pupae (Fig. 3B & C), secretion is 
dramatically decreased in pupae expressing mRFP-HttQ138 (Fig. 3D), suggesting 
severe salivary gland dysfunction.  Normal 3rd instar larval salivary gland cells are filled 
with glue (Fig. 3E) that is depleted during pupariation (Fig. 3F); however, the pupal 
salivary glands of mRFP-HttQ138-expressing larvae retain glue (Fig. 3G), further 
indicating salivary gland dysfunction mediated by mutant Htt in the cytoplasm.  
 
The 588 aa fragment of mutant human Htt does not show evidence of cleavage in 
Drosophila  
Many previous studies of HD have focused on nuclear aggregates, as opposed 
to the cytoplasmic aggregates observed in our model.  Htt is known to undergo cleavage 
by caspases and calpains into N-terminal fragments that are found in both the nucleus 
and the cytoplasm (Gafni et al., 2004; Kim et al., 2001; Lunkes et al., 2002; Wellington et 
al., 2002).  Cleavage is thought to be an essential step in the generation of toxic Htt 
fragments (Qin and Gu, 2004); however, the size(s) of truncated Htt fragments 
responsible for HD pathology remain to be identified.  To determine whether cleavage of 
the N-terminal 588 aa of Htt occurs in our fly model, S2 cells were transiently transfected 
with 588 aa Htt constructs labeled with eGFP at the N-terminus and mRFP at the C-
terminus.  Complete colocalization of the eGFP and mRFP signals is seen for both the 
normal eGFP-HttQ15-mRFP fragment and the mutant eGFP-HttQ138-mRFP fragment 
(Fig. 4A), suggesting that cleavage of the proteins does not occur in the context of 
Drosophila. 
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FIGURE 2. Cytoplasmic aggregation of mRFP-HttQ138 in neuronal and non-
neuronal tissues.  (A) Htt localization in Drosophila S2 cells transiently transfected with 
mRFP-HttQ15 or mRFP-HttQ138.  mRFP-HttQ15 is found diffusely throughout the 
cytoplasm, while mRFP-HttQ138 forms cytoplasmic aggregates.  (B) Visualization of 
mRFP-HttQ15 (magenta) and GFP with a nuclear localization signal (nls) (green) in 3rd 
instar larvae with transgene expression driven by the C155 elav-GAL4 driver.  mRFP-
HttQ15 is diffusely localized in the cytoplasm of CNS neurons in the ventral nerve cord.  
(C) Visualization of mRFP-HttQ138 (magenta) and GFP-nls (green) in CNS neurons of 
3rd instar larvae with transgene expression driven by the C155 elav-GAL4 driver.  Unlike 
mRFP-HttQ15, mRFP-HttQ138 forms cytoplasmic aggregates throughout the cell bodies 
of ventral nerve cord neurons.  (D, E) Visualization of mRFP-Htt in peripheral MD 
neurons.  While mRFP-HttQ15 exhibits diffuse cytoplasmic localization, mRFP-HttQ138 
is found in cytoplasmic aggregates throughout the cell body and neurites.  (F-I) 
Expression of mRFP-Htt (magenta) and GFP-nls (green) driven by the tubP-GAL4 driver 
in the epidermis (F, G) and salivary gland (H, I).  In all cases, mRFP-HttQ15 is diffuse 
throughout the cytoplasm, while mRFP-HttQ138 forms cytoplasmic aggregates.   
 126
 127
FIGURE 3. Salivary gland glue secretion is defective in Drosophila expressing 
mRFP-HttQ138.  (A) Diagram of normal glue secretion during pupariation.  Expression 
of the glue protein fused to GFP enables in vivo imaging of secreted glue. (B) Secretion 
of glue (green) is normal in control pupae.  (C) Secretion of glue (green) is also normal in 
pupae expressing mRFP-HttQ15 (red).  Glue-GFP is indicated by arrows, while mRFP-
HttQ15-filled salivary glands are indicated by arrowheads.  Expansion of the polyQ tract 
in Htt is necessary to induce glue secretion defects, as Htt is abundantly present in the 
salivary glands of mRFP-HttQ15-expressing animals, but does not impair secretion of 
glue-GFP. (D) Secretion of glue (green) is strikingly decreased in pupae expressing 
mRFP-HttQ138 (red).  Arrows indicate the presence of glue-GFP in the salivary glands 
where mRFP-HttQ138 is also expressed (indicated by arrowheads).  (E) Normal 3rd 
instar salivary gland cells contain glue that is depleted during pupariation (F).  However, 
the pupal salivary glands of mRFP-HttQ138-expressing animals retain glue (G). 
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FIGURE 4. The 588 aa fragment of mutant human Htt does not show evidence of 
cleavage in Drosophila.  (A) Transient transfection of Drosophila S2 cells with eGFP-
HttQ138-mRFP demonstrates no separation of eGFP (green) and mRFP (magenta) 
signals, indicating that the ends of the 588 aa fragment of mutant Htt protein colocalize 
and that there is no evidence for cleavage of the fragment.  Visualization of signal 
localization in 3rd instar larvae with expression of eGFP-HttQ138-mRFP driven by the 
C155 elav-GAL4 driver shows no separation of eGFP (green) and mRFP (magenta) 
signals in brain lobe CNS neurons (B), salivary gland cells (C), or epidermal cells (D). 
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To assess whether cleavage occurs in vivo, we generated transgenic strains 
expressing the double-labeled mutant Htt fragment eGFP-HttQ138-mRFP.  As observed 
in the S2 cell model, eGFP and mRFP signals colocalized in all tissues studied, 
including CNS neurons (Fig. 4B), salivary gland cells (Fig. 4C), and epidermal cells (Fig. 
4D), demonstrating colocalization of both ends of the mutant Htt protein and suggesting 
that cleavage of the mutant Htt protein does not occur in vivo in Drosophila.  No 
fluorescent signal is seen in the nucleus, indicating that even if cleavage does occur, the 
mutant Htt-mediated toxicity observed in our 588 aa transgenic lines reflects a specific 
effect of mutant Htt on cytoplasmic processes. 
 
Exon 1 of mutant Htt forms cytoplasmic and neuritic aggregates  
Upon cleavage of Htt in HD tissue, the smallest N-terminal fragments are thought 
to enter the nucleus and form neuronal intranuclear inclusions (NIIs) (DiFiglia et al., 
1997; Sieradzan et al., 1999).  These intranuclear inclusions are postulated to play a role 
in HD pathology (Becher et al., 1998; Davies et al., 1997), and are found in many HD 
models expressing exon 1 of the mutant Htt protein.  (Davies et al., 1997; Jackson et al., 
1998; Krobitsch and Lindquist, 2000; Tagawa et al., 2004).  To determine whether the in 
vivo subcellular localization of the 81 aa exon 1 fragment of mutant human Htt (HttQ96-
GFP) differs from that of the 588 aa mutant Htt fragment, HttQ96-GFP-expressing 3rd 
instar larvae were imaged using confocal microscopy.  In both neuronal and non-
neuronal cell types, HttQ96-GFP formed distinct cytoplasmic aggregates identical in 
appearance and localization to those formed by the 588 aa mRFP-HttQ138 protein.  
GFP-labeled aggregates are found in the cytoplasm of salivary gland cells (Fig. 5B) and 
epidermal cells (Fig. 5G), as well as in CNS (Fig. 5D) and PNS (Fig. 5F) neurons.  As 
observed with the 588 aa fragment, the exon 1 fragment is also observed in axons (Fig. 
5E) and localizes at nerve terminals.  The non-nuclear localization of mutant Htt in 
mRFP-HttQ138 and HttQ96-GFP flies provides an ideal system to characterize the 
consequences of aggregate formation in the cytoplasm and neurites on neuronal 
function.   
 
Mutant Htt causes physical blockage of axonal transport and is differentially 
transported compared to normal Htt 
The presence of mutant Htt aggregates in the axon may impair neuronal function 
by sequestering axonal or synaptic proteins or by physically blocking transport in 
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individual axons.  In order to determine whether the diameter of accumulations of 
aggregates within the axon is sufficient to block axonal transport, we expressed the 
mutant HttQ96-GFP protein with a motor axon GAL4 driver, allowing the visualization of 
UAS-HttQ96-GFP aggregates in single axons in 3rd instar larvae.  By co-expressing 
UAS-RFP in the motor axon to define its structure, it is clear that large aggregate 
accumulations exceed the diameter of individual axons and cause the axon to swell 
around the aggregates, in concordance with physical axonal blockage (Fig. 6A-C).  
While wild-type Htt undergoes both anterograde and retrograde transport (Block-Galarza 
et al., 1997), long-term imaging of aggregates in live 3rd instar larvae demonstrated that 
large aggregate accumulations are immobile within the axon, indicating that they may 
block traffic in both directions (Fig. 6D).  Driving expression of transgenes in aCC 
neurons with the eve-GAL4 driver allows for visualization of both axons and dendrites. In 
mRFP-HttQ138-expressing animals, mutant Htt aggregates are observed in the dendritic 
arbor as well as in axons (Fig. 6E), suggesting that Htt aggregates may cause 
deleterious effects on trafficking in both dendrites and axons.      
To characterize the effects of Htt on axonal transport, we analyzed the trafficking 
of normal and mutant Htt in vivo.  Movement of mRFP-HttQ15 and mRFP-HttQ138 
transport particles can readily be visualized in vivo in the motor axons of 3rd instar 
larvae.  Within these axons, transport particles of Htt move in a saltatory manner, with 
short runs in both anterograde and retrograde directions.  Several different variables of 
movement for each direction, including percentage of time spent traveling in each 
direction, mean velocity, mean duration of runs, and mean length of runs, were 
measured for both mRFP-HttQ15- and mRFP-HttQ138-expressing animals (Table 1).  
An analysis of mRFP-HttQ15 and mRFP-HttQ138 movement revealed striking 
differences in axonal transport of normal and mutant Htt.  The most significant difference 
observed was an increase in the duration of retrograde runs and the length of axon 
traveled per retrograde run for mutant Htt particles compared to normal Htt.  In addition, 
anterograde velocity of mRFP-HttQ138 particles was decreased, with a ~6-fold increase 
in the duration of pauses during anterograde movement compared to mRFP-HttQ15 
particles.  Mutant Htt is known to undergo an increased interaction with huntingtin-
associated protein 1 (HAP1) (Li et al., 1995), which binds to p150glued, an accessory 
protein for dynein that is involved in retrograde transport (Engelender et al., 1997; Li et 
al., 1998).  Our findings suggest that increased binding of mutant Htt to retrograde 
transport molecules may increase the duration and length of retrograde runs of mutant 
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FIGURE 5. Cytoplasmic aggregation of HttQ96-GFP in neuronal and non-neuronal 
tissues.  (A) Visualization of GFP (green) in the salivary gland.  GFP is found in both the 
cytoplasm and the nucleus.  The nucleus is indicated by N.  (B) Visualization of HttQ96-
GFP (green) in the salivary gland.  Unlike GFP alone, HttQ96-GFP forms cytoplasmic 
aggregates in the salivary gland.  The nucleus is indicated by N and aggregates are 
indicated by arrowheads.  (C, D) Visualization of GFP and HttQ96-GFP in CNS neurons 
of the ventral nerve cord.  GFP is diffusely localized in ventral nerve cord cells, while 
HttQ96-GFP forms aggregates.  Aggregates are indicated by arrowheads.  (E)  HttQ96-
GFP aggregates (green, indicated by arrowheads) are found in axons labeled with 
dsRed (magenta).  (F) In epidermal cells, GFP (green) is diffuse in the cytoplasm.  (G) 
HttQ96-GFP (green) is found in cytoplasmic aggregates (indicated by aggregates) in 
epidermal cells. 
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FIGURE 6. Blockage of axons by mutant Htt aggregates.  (A-C)  Blockage of axons 
by mutant Htt aggregates.  With transgene expression driven in individual motor axons 
by the RRa-GAL4 driver, the accumulation of HttQ96-GFP aggregates (green, indicated 
by the arrowhead) exceeds the diameter of the axon (magenta) and causes it to swell 
outwards.  (D) mRFP-HttQ138 aggregates are immobile in the axon.  In live 3rd instar 
larvae with transgene expression driven by the C155 elav-GAL4 driver, HttQ96-GFP 
aggregates (green, indicated by arrows) are located in the same area of the axon at 0 
seconds and at 1 hour, indicating that the aggregates are immobile.  (E) Mutant Htt 
aggregates are found in both axons and dendrites.  Expression of GFP (green) and 
mRFP-HttQ138 (magenta) with the eve-GAL4 driver demonstrates localization of mRFP-
HttQ138 aggregates in both axons (indicated by small arrowheads) and dendrites 
(indicated by the large arrowhead) in RP2 neurons.   
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Htt-associated cargoes, while decreasing anterograde velocity and increasing the 
duration of anterograde pauses.  These defects raise the possibility of non-aggregate-
dependent alterations in axonal transport, in addition to physical blocks from large, non-
motile aggregates. 
 
Axonal transport cargoes are trapped by accumulations of mutant Htt aggregates 
If aggregates are causing a physical blockage of axonal transport, axonal 
cargoes should be obstructed by sites of larger Htt aggregate accumulations that 
approach or exceed the diameter of the axon, but not by smaller accumulations.  We 
coexpressed several GFP-tagged proteins that normally undergo axonal trafficking in the 
context of either the normal mRFP-HttQ15 protein or the mutant mRFP-HttQ138 protein 
to observe their localization within the axon.  While all of the cargoes display diffuse or 
punctuate staining when coexpressed with mRFP-HttQ15, cargoes clearly colocalize 
with larger areas of mRFP-HttQ138 aggregate accumulation in the case of the dense 
core vesicle marker ANF (Fig. 7A), synaptic vesicle markers synaptotagmin (Fig. 7B) 
and synaptobrevin (Fig. 7C), clathrin-coated vesicle marker Chc (Fig. 7D), and the 
endosomal marker Rab11 (Fig. 7E).  mRFP-HttQ138 aggregates are also able to 
sequester cytosolic proteins such as Drosophila complexin (Fig. 7F).  Axonal swellings 
seen around accumulations of aggregates suggest that large Htt accumulations block 
and distort axons, sequestering a variety of cargoes required for normal synaptic 
function.  
 
Aggregate-dependent versus –independent axonal transport defects vary with 
specific cargo 
Mutant Htt may cause defects in axonal transport through aggregate-
independent means, including loss of normal Htt function (Gunawardena et al., 2003; 
Trushina et al., 2004) or sequestration of key transport proteins (Trushina et al., 2004).  
To address this possibility in our Drosophila model, we imaged sites of synaptotagmin 
accumulation, marking areas of impaired axonal transport, in 100 μM axon segments of 
mRFP-HttQ15- and mRFP-HttQ138-expressing 3rd instar larvae.  Sites of colocalization 
between synaptotagmin accumulations and Htt can be differentiated from sites of Htt-
independent synaptotagmin accumulation, providing a method to compare aggregate-
dependent and aggregate-independent blockages.  If expression of mutant Htt results in 
general, aggregate-independent transport defects, the number of aggregate-
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FIGURE 7. Mutant Htt aggregates trap axonal transport cargo.  Coexpression of 
mRFP-HttQ15 or mRFP-HttQ138 (magenta) with various axonal transport cargoes 
(green) was driven by the C155 elav-GAL4 driver.  (A) Dense core vesicles, labeled by 
ANF-GFP (green), colocalize with mRFP-HttQ138 aggregates (magenta) in areas 
indicated by the arrows.  (B-C) Synaptic vesicles, labeled by Syt1-GFP or Syb-GFP 
(green), colocalize with mRFP-HttQ138 aggregates (magenta) in areas indicated by the 
arrows.  Colocalization with mRFP-HttQ138 aggregates (magenta) is also seen for 
clathrin-coated vesicles, labeled by Chc-GFP (green) (D), endosomes, labeled by 
Rab11-GFP (green) (E), and cytosolic proteins such as complexin (green) (F).
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FIGURE 8. Effects of mutant Htt expression on vesicular transport.  (A) To 
determine the effect of mutant Htt expression of synaptic vesicle transport, areas of 
accumulation for mRFP-HttQ138 alone, Syt1-GFP alone, and areas where mRFP-
HttQ138 and Syt1-GFP accumulations colocalized were quantified per 100 μm motor 
axon segment for 30 segments.  Bars indicate SEM.  (B) To determine the effect of 
mutant Htt expression on dense core vesicle transport, areas of accumulation for mRFP-
HttQ138 alone, ANF-GFP alone, and areas of colocalization between mRFP-HttQ138 
and ANF-GFP accumulations were quantified per 100 μm motor axon segment for 30 
segments.  Bars indicate standard error. (C) Visualization of ANF-GFP (green) in motor 
axon segments.  Non-aggregate-associated ANF-GFP levels are visibly decreased in 
motor axons of animals expressing mRFP-HttQ138 (magenta) compared to animals 
expressing mRFP-HttQ15 (magenta). 
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independent synaptotagmin accumulations in mRFP-HttQ138-expressing animals 
should exceed that of mRFP-HttQ15-expressing animals.  However, no difference is 
seen between numbers of non-Htt-colocalized synaptotagmin accumulations between 
mRFP-HttQ15 and mRFP-HttQ138 (Fig. 8A), suggesting that impairment of axonal 
transport of synaptic vesicle proteins is predominately due to aggregate-dependent 
physical blockage of the axon. 
In contrast to results observed with the synaptic vesicle marker synaptotagmin, 
visualization of the dense core vesicle marker ANF in 100 μM segments of axon 
suggests that expression of mutant Htt may also affect axonal transport in an aggregate-
independent manner.  A striking decrease in the number of dense core vesicles per 100 
μM segment of axon is observed in mRFP-HttQ138-expressing lines as compared to 
mRFP-HttQ15-expressing lines (Fig. 8B & C).  There is no significant increase in the 
number of aggregate-independent blockage sites, suggesting that the decrease in 
vesicle number is not due to a general defect in axonal transport, but may instead be 
due to mutant Htt-mediated disruption of interactions between dense core vesicles and 
transport machinery within the axon. 
 
Mitochondrial transport is disrupted in mRFP-HttQ138-expressing animals 
In addition to defects in dense core vesicle transport, mRFP-HttQ138-expressing 
animals also exhibit defects in mitochondrial transport.  Mitochondria continuously attach 
to and detach from axonal transport systems in order to localize to sites where they are 
needed for calcium buffering or ATP production in the axon or synapse (Hollenbeck and 
Saxton, 2005).  Thus, regulation of mitochondrial transport is essential to the health of 
the neuron.  To observe the localization of mitochondria in axons of mutant Htt-
expressing animals, mRFP-HttQ138-expressing flies were crossed to flies expressing 
mitochondria tagged with GFP (mito-GFP).  Mitochondria were observed to colocalize 
more with mRFP-HttQ15 than with mRFP-HttQ138 (Fig. 9A & B), suggesting that normal 
Htt may interact with mitochondria and that mutation of Htt may reduce this interaction.  
In concordance with a role for normal Htt in mitochondrial trafficking, observation of in 
vivo transport in the motor axons of 3rd instar larvae revealed colocalized movement 
between mito-GFP and a subset of mRFP-HttQ15 transport particles (unpublished data).  
However, most mRFP-HttQ15 particles move independently of mito-GFP, suggesting 
that mitochondria may represent only a subset of normal Htt-dependent cargo.  
Interestingly, a significant reduction in the number of axonal mitochondria was seen in 
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mRFP-HttQ138-expressing lines in comparison to mRFP-HttQ15-expressing lines (Fig. 
9C & D), indicating that disruption of the interaction between normal Htt and 
mitochondria may reduce mitochondrial transport within the axon. 
 
Mutant Htt aggregates sequester normal Htt 
If normal Htt plays a role in axonal transport of mitochondria or other transport 
cargoes, Htt mutation may cause trafficking defects by decreasing the amount of 
normally functioning Htt within the axon.  This could occur through haploinsufficiency 
and/or through interference of mutant Htt with normal Htt function.  To determine 
whether mutant Htt is able to recruit normal Htt into aggregates, 3rd instar larvae 
expressing both mRFP-HttQ138 and eGFP-HttQ15 were imaged to visualize the 
localization of mutant and normal Htt coexpressed within the same tissue.  While eGFP-
HttQ15 expressed by itself exhibits a diffuse cytoplasmic localization pattern, eGFP-
HttQ15 expressed in the presence of mRFP-HttQ138 becomes partially recruited into 
mutant Htt aggregates in salivary glands (Fig. 10A) and, importantly, in axons (Fig. 10B), 
where sequestration of normal Htt could interfere with its putative role in axonal 
transport.  This suggests that mutant Htt may disrupt normal Htt function in a dominant 
negative manner and that HD may in part be caused by loss of function of the normal Htt 
protein. 
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FIGURE 9. Mutant Htt affects mitochondrial localization.  (A) In vivo visualization of 
mitochondria in motor axons of 3rd instar larvae coexpressing mRFP-HttQ15 (magenta) 
with GFP-tagged mitochondria (mito-GFP, green) driven by the C155 elav-GAL4 driver. 
Partial colocalization of mRFP-HttQ15 with mitochondria is seen.  (B) In 3rd instar larve 
coexpressing mRFP-HttQ138 (magenta) and mito-GFP (green), less colocalization is 
seen.  (C) In mRFP-HttQ15-expressing animals, mito-GFP (green) is abundant within 
motor axons.  (D) In comparison, mRFP-HttQ138-expressing animals exhibit a lower 
concentration of mito-GFP in motor axons.  
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FIGURE 10. Mutant Htt aggregates sequester normal Htt.  In 3rd instar larvae 
coexpressing mRFP-HttQ138 and eGFP-HttQ15 with the C155 elav-GAL4 driver, eGFP-
HttQ15 (green) colocalizes with mRFP-HttQ138 aggregates (rmagenta) in salivary gland 
cells (A) and motor axons (B). 
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Discussion  
 
Overview 
 
Many neurodegenerative diseases caused by protein misfolding have been 
modeled in Drosophila, including Parkinson’s disease (Feany and Bender, 2000), 
Alzheimer’s disease (Wittmann et al., 2001), spinocerebeller ataxia type 1 (Fernandez-
Funez et al., 2000) and type 3 (Warrick et al., 1999), and Huntington’s disease 
(Gunawardena et al., 2003; Jackson et al., 1998; Lee et al., 2004; Steffan et al., 2001).  
These models replicate neuropathological features characteristic of the diseases, such 
as late onset, progressive neurodegeneration, and formation of inclusions containing the 
mutant protein.  Development of such disease models may facilitate the identification of 
molecular pathways that lead to neurodegeneration in the corresponding human 
disorders. 
We have demonstrated formation of non-nuclear aggregates in Drosophila HD 
models expressing either 588 aa or 81 aa N-terminal fragments of mutant Htt, providing 
an ideal in vivo environment in which to study the role of Htt aggregates in the cytoplasm 
and neurites and the effects of mutant Htt expression on axonal transport.  
Accumulations of mutant Htt aggregates exceed the diameter of motor axons, indicating 
a physical blockage of axonal transport.  Visualization of both vesicular and cytosolic 
GFP-tagged axonal transport cargoes reveals abnormal accumulation of cargoes at sites 
where aggregates physically block the axon.  In the case of synaptic vesicles, 
aggregate-independent cargo accumulations do not increase in the presence of mutant 
Htt as compared to normal Htt, suggesting that accumulation of synaptic vesicles at sites 
colocalizing with Htt aggregates results from physical blockage by aggregates rather 
than from general, blockage-independent effects of mutant Htt on transport. 
In addition to physical blockage of axonal trafficking through accumulation of Htt 
aggregates in the axon, mutant Htt also decreases the association of certain transport 
cargoes with the axonal transport machinery.  The concentration of both dense core 
vesicles and mitochondria is reduced in motor axons of mutant Htt-expressing animals, 
suggesting that mutation of Htt disrupts the ability of these cargoes to interact with motor 
protein complexes and undergo transport from the cytosol into the axon.  This may be 
caused by loss of wild-type Htt function in axonal transport or by abnormal properties of 
mutant Htt.  Coexpression of normal with mutant Htt demonstrates that normal Htt can 
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be sequestered by mutant Htt aggregates, suggesting that pathology may be caused by 
aggregation of Htt and by loss of normal Htt function through recruitment into 
aggregates. 
 
Axonal transport defects in HD 
In HD, aggregates of mutant Htt are found in both the nucleus and cytoplasm of 
neurons in the striatum and cortex.  While nuclear aggregate-mediated impairment of 
transcription is proposed to play a key role in polyQ disease neuropathology (Ross, 
2002), several lines of evidence indicate that the presence of aggregates in the nucleus 
does not correlate with neurodegeneration (Klement et al., 1998; Saudou et al., 1998).  
Indeed, in HD, formation of neuropil aggregates is more highly correlated with neuronal 
dysfunction (Li et al., 1999a).  In addition, neuritic degeneration precedes cell body 
degeneration in cultured striatal neurons (Li et al., 2001), and is observed in 
presymptomatic HD patients (Albin et al., 1990), indicating a potential role for neuropil 
aggregates in early HD pathology.   
Axons may be particularly vulnerable to aggregate-mediated pathology.  Defects 
in axonal transport have been implicated in a number of neurodegenerative diseases, 
including HD, Alzheimer’s disease, Parkinson’s disease, and motor neuron diseases 
(Raff et al., 2002).    Neurons rely on axonal trafficking over long distances to support the 
axon and the synapse and to deliver survival signals from the synapse to the cell body; 
bidirectional blockage of transport by aggregates may result in synaptic dysfunction, 
axonal degeneration, and cell death.  Indeed, loss of axonal motor proteins, including 
kinesin, dynein, and dynactin, can cause neurodegenerative phenotypes (Hafezparast et 
al., 2003; LaMonte et al., 2002; Reid et al., 2002; Zhao et al., 2001).  Htt aggregates in 
the axon have been shown to block transport of exogenous markers (Li et al., 2001), 
synaptic vesicles (Lee et al., 2004), and organelles (Chang et al., 2006).  Our data 
provides evidence for aggregate-dependent blockage of synaptic vesicles, dense core 
vesicles, clathrin-coated vesicles, endosomes, and cytoplasmic proteins, indicating that 
Htt aggregates within the axon cause widespread impairment of axonal trafficking.  
While aggregates may not be toxic in the cell body, and may indeed serve a 
neuroprotective role (Arrasate et al., 2004), aggregates in the axon may block axonal 
transport and contribute to HD pathogenesis.   
In addition to aggregate-dependent impairment of axonal transport, loss of wild-
type Htt may also result in axonal trafficking defects.  Although the precise function of Htt 
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has yet to be determined, the protein is enriched in membrane-containing compartments 
(DiFiglia et al., 1995), is transported in both anterograde and retrograde directions 
(Block-Galarza et al., 1997), and interacts with microtubules (DiFiglia et al., 1995) and 
the p150glued component of dynactin (via HAP1) (Engelender et al., 1997; Li et al., 
1998), suggesting that it may be vital for axonal trafficking.  Decreasing normal Htt 
function has been shown to impair axonal trafficking in Drosophila (Gunawardena et al., 
2003) and mammalian neurons (Trushina et al., 2004), and recent data suggests that 
wild-type Htt may play a role in transport of BDNF, a neurotrophic support molecule 
(Gauthier et al., 2004).  We have shown that mutant Htt aggregates are able to 
sequester normal Htt, indicating that axonal transport defects seen in HD may be due 
not only to physical blockage by mutant Htt aggregates and disrupted interactions 
between mutant Htt and Htt binding partners, but also mutant Htt-mediated loss of 
normal Htt function. 
Effects of impaired axonal transport can be severe.  In mice expressing mutant 
Htt, a decrease of density in synaptic vesicles is seen at synapses in the brain, resulting 
in decreased neurotransmitter release (Li et al., 2003a).  Such synaptic dysfunction may 
play a role in the acute motor and cognitive deficits seen in HD before widespread 
neuronal loss.  Additionally, defects in axonal transport can result in a lack of axonal 
support and maintenance.   Axonal damage and subsequent degeneration are seen in a 
variety of neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s 
disease, motor neuron disease, and Huntington’s disease (Raff et al., 2002).  
Degeneration of the axon prevents the transport of neurotrophic factors from the 
synapse to the cell body, leading to neuronal death, and may be responsible for the 
neurodegenerative phenotypes seen in these diseases. 
 
Mitochondrial transport defects in HD 
One specialized role of axonal transport is the trafficking of mitochondria to and 
from the axon and synapse.  The dynamic distribution of mitochondria is carefully 
regulated in order to ensure that the organelles are targeted to areas of the neuron with 
energy or calcium buffering needs.  Recent studies suggest that normal Htt may play a 
role in axonal trafficking of mitochondria; a 50% decrease in wild-type Htt results in a 
decrease in the motility of mitochondria (Trushina et al., 2004).  Additionally, in 
Drosophila lacking Milton, the Drosophila homologue of HAP1, mitochondria fail to enter 
the axon and remain in the cell body (Stowers et al., 2002), suggesting a link between 
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Htt and mitochondrial transport in the axon.  In Drosophila expressing mutant Htt, we 
have observed a defect in mitochondrial transport in motor axons.  While normal Htt is 
seen to colocalize with mitochondria in the axon, colocalization of mitochondria with 
mutant Htt is reduced, indicating that expansion of the polyglutamine repeat in the Htt 
protein may disrupt a potential interaction of Htt with mitochondria.  We have also 
observed a decrease in the density of mitochondria within the axon in mutant Htt-
expressing animals.  A similar decrease was observed in the number of mitochondria 
entering Htt aggregate-containing segments of axon in cortical neurons (Chang et al., 
2006).  Mutation of Htt may limit or abolish its normal function in axonal transport.  
Alternatively, aggregates of mutant Htt could disrupt transport by sequestering 
mitochondria (Chang et al., 2006), or by titrating normal Htt or other mitochondrial 
trafficking proteins in the axon, leading to pathological defects in mitochondrial 
distribution in the axon and at the synapse. 
Proper distribution of mitochondria in the axon is essential to neuronal health.  
Mitochondria with high membrane potential necessary for ATP production move towards 
the synapse, while old or damaged mitochondria are transported back to the cell body 
for repair or autophagy (Miller and Sheetz, 2004).  Defects in mitochondrial transport 
may have a twofold effect: first, lack of healthy mitochondria at sites of high energy 
demand or tight calcium regulation, such as the axon and the synapse, will keep the 
metabolic and calcium buffering needs of the neuron from being met.  Sufficient ATP 
production is necessary for maintenance of ionic and voltage gradients and for the 
activity of many cellular components, while proper calcium buffering is important for 
many neuronal functions and plays an essential role in synaptic plasticity; defects in 
calcium homeostasis caused by impaired mitochondrial buffering may contribute to 
cognitive defects seen in HD.  Second, failure to recycle aged or damaged mitochondria 
may lead to mitochondrial production of reactive oxygen species and release of 
cytochrome C, resulting in apoptotic death of neurons (Lee and Wei, 2000).  Indeed, 
mice expressing the mutant Htt protein exhibit degenerated mitochondria in axons (Li et 
al., 2001) and at axon terminals (Li et al., 2003a), and several studies indicate that 
mitochondrial function is impaired in mutant Htt-expressing models (Grunewald and 
Beal, 1999), providing evidence that aged/damaged mitochondria are not properly 
processed in HD neurons.  Additionally, systemic administration of mitochondrial toxins 
to rodents and primates causes HD-like pathology, including striatal lesions and 
choreiform movement disorders (Browne and Beal, 2004), further suggesting a role for 
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mitochondrial dysfunction in HD.  Impairment of mitochondrial transport, by depriving the 
axon of healthy mitochondria while failing to remove degenerated mitochondria, may 
play a key role in causing the cognitive and motor defects and neuropathology seen in 
HD. 
 
In vivo rates of Htt transport 
Using fluorescently-tagged normal and mutant Htt, we were able to visualize 
transport of Htt particles in vivo in Drosophila.  While mutant Htt aggregates remain 
immobile, transport particles of both normal and mutant Htt undergo saltatory, 
bidirectional patterns of movement.  Strikingly, transport particles of mutant Htt exhibit a 
dramatic increase in the duration of retrograde runs and in the length of axon traveled 
per retrograde run in comparison to normal Htt.  Additionally, the anterograde velocity of 
mutant Htt particles is decreased, while duration of pauses during anterograde runs is 
increased.  One possible explanation lies in the fact that mutant Htt binds HAP1 more 
tightly than normal Htt (Li et al., 1995); HAP1 directly interacts with p150glued, the 
largest component of the dynactin complex, which is required by dynein for retrograde 
transport (Li et al., 1998).  The increased duration and length traveled for retrograde 
runs and decreased velocity and longer pauses in anterograde runs may reflect tighter 
binding of mutant Htt to the retrograde transport machinery.  If Htt normally functions in 
axonal transport, changes in transport variables for Htt may impact the trafficking of all 
Htt-associated cargoes.  Future studies will test for colocalization of movement between 
Htt transport particles and fluorescently-tagged transport cargoes in order to determine a 
subset of cargoes requiring Htt for transport, further clarifying the role of Htt in axonal 
trafficking.  In addition, visualization of potential changes in transport of these cargoes in 
a mutant Htt background may elucidate cellular pathways that lead to HD pathology. 
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Future Directions 
 
Our data indicates that wild-type Htt may have a role in axonal transport of 
cargoes including mitochondria and dense core vesicles.  Future studies will focus on 
real-time imaging of in vivo axonal transport with fluorescently-tagged Htt and cargo 
proteins.  Observation of cotransport between wild-type Htt and cargo may help to define 
the normal role of Htt in axonal trafficking, while effects of mutant Htt expression on 
transport may elucidate aggregate-dependent and –independent ways in which axonal 
transport defects contribute to HD pathogenesis.  In addition, generation of a 
fluorescently-tagged version of the Drosophila Htt homologue may provide the most 
relevant information regarding normal Htt transport activity in vivo in flies. 
Future work will also include electrophysiological analysis of mRFP-Htt-
expressing lines.  Interestingly, the ability to visualize Htt localization at the 3rd instar 
neuromuscular junction (NMJ) synapse has led to the observation that approximately 
one-third of these synapses contain abundant levels of Htt (Fig. 11A) while the other 
two-thirds exhibit no discernible Htt presence (Fig. 11B).  Distribution of synapses with 
and without Htt appears to be random in each larva.   
The ability to differentiate between synapses that physically contain Htt and 
those that do not enables us to perform a detailed analysis of the role of mutant Htt in 
synaptic pathology.  Synaptic dysfunction limited to synapses containing mutant Htt 
would indicate that toxic effects are exerted at the synapse, whereas if synaptic defects 
are seen in all synapses of animals expressing mutant Htt, regardless of visible Htt 
presence, this may suggest mutant Htt-mediated dysfunction at the level of axonal 
transport or even at the level of gene transcription.  Studies will include analysis of 
miniature excitatory junctional potentials (mEJPs), excitatory junctional potentials 
(EJPs), paired-pulse facilitation, and high-frequency stimulation, in order to examine the 
effect of mutant Htt on spontaneous vesicle fusion, basal neurotransmitter release, 
plasticity, and vesicle recyling, respectively.  If synaptic dysfunction requires the 
presence of mutant Htt at synapses, it may be possible to alleviate HD pathology by 
preventing localization of mutant Htt to synaptic terminals. 
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FIGURE 11. Localization of mutant Htt to larval NMJ synapses is stochastic.  (A) 
Approximately one-third of muscle 6/7 NMJ synapses in 3rd instar larvae exhibit 
abundant levels of mRFP-HttQ138 (red).  (B) mRFP-HttQ138 (red) is not observed at 
two-thirds of muscle 6/7 NMJ synapses.  Muscles are stained with Alexa Fluor® 488 
phalloidin (green). 
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Abstract 
 
Conservation of cellular pathways and disease mechanisms between humans and 
Drosophila has led to the wide use of Drosophila disease models for the development 
and testing of potential therapies.  Our Drosophila HD model provides an ideal in vivo 
environment in which to test chemical and molecular mediators of mutant Htt-induced 
pathology.  To assay the therapeutic effect of expression of an intracellular antibody 
(intrabody) against Htt, we generated double transgenic lines coexpressing pathogenic 
Htt (mRFP-HttQ138) with the intrabody.  Intrabody expression caused suppression of 
aggregation in both neuronal and non-neuronal cell types, but failed to rescue mutant 
Htt-mediated cellular dysfunction, suggesting that mutant Htt can exert toxic effects in 
non-aggregated form. 
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Introduction 
 
Currently, no effective therapies exist for Huntington’s disease.  The wealth of 
new knowledge regarding the pathomechanisms of the disease have led to the 
development of numerous therapeutic strategies; some aim to inhibit the aggregation of 
mutant Htt, while others target different pathways affected by the disease.  Because the 
wild-type Htt protein is known to be essential for neuronal survival and function 
(Dragatsis et al., 2000; O'Kusky et al., 1999), a key consideration in the design of 
therapies is selective targeting of the toxic effects of the mutant protein without 
disruption of normal protein activity.  New understanding of the molecular basis of the 
disease will help to define effective therapeutic targets. 
One obvious target in the design of HD therapies is aggregation of the mutant Htt 
protein.  While it is still debated whether aggregates are toxic, neuroprotective, or merely 
a byproduct of the disease process, studies indicate that many compounds that 
suppress aggregation also rescue mutant Htt-mediated toxicity.  Our observations of 
aggregate-dependent blocks in axonal transport support this approach.  Drugs such as 
Congo Red (Heiser et al., 2000; Sanchez et al., 2003), minocycline (Chen et al., 2000; 
Smith et al., 2003), and the transglutaminase inhibitor cystamine (Dedeoglu et al., 2002) 
are able to block aggregation of mutant Htt and rescue behavioral phenotypes in R6/2 
mice.  Both molecular (Cummings et al., 2001; Fernandez-Funez et al., 2000; Jana et 
al., 2000; Vacher et al., 2005; Warrick et al., 1999) and chemical (Yoshida et al., 2002) 
chaperones have also been shown to diminish aggregate formation and reduce 
cytotoxicity in polyQ disease models.  Chemical compounds (Wang et al., 2005; Zhang 
et al., 2005), small peptides (Kazantsev et al., 2002; Nagai et al., 2000), and intracellular 
antibodies (Colby et al., 2004b; Khoshnan et al., 2002; Lecerf et al., 2001; Wolfgang et 
al., 2005) can be engineered and/or screened for binding to mutant Htt epitopes and 
suppression of aggregate formation.  In addition, knocking down expression of mutant 
Htt with RNAi inhibits aggregation and rescues motor phenotypes in mouse HD models 
(Harper et al., 2005; Rodriguez-Lebron et al., 2005), and offers the possibility of mutant 
allele-specific targeting (Rodriguez-Lebron and Paulson, 2006).  Interestingly, a recent 
study indicates that promotion, rather than suppression, of aggregate formation may 
lessen HD neuropathology by rescuing proteasome function (Bodner et al., 2006). 
Molecular pathways known to be involved in HD pathogenesis also provide 
potential targets for the development of HD therapies.  Histone deacetylase inhibitors 
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such as suberoylanilide hydroxamic acid (SAHA) and butyrate counteract mutant Htt-
mediated transcriptional dysregulation and reduce polyQ toxicity in cell culture 
(McCampbell et al., 2001), yeast (Hughes et al., 2001) Drosophila (Steffan et al., 2001), 
and mice (Ferrante et al., 2003; Hockly et al., 2003a).  Caspase inhibitors such as 
cystamine (Dedeoglu et al., 2002) and minocycline (Chen et al., 2000) reduce aggregate 
number and behavioral abnormalities.  Compounds that target the metabolic and 
mitochondrial defects observed in HD include dichloroacetate, creatine, and co-enzyme 
Q, and have been effective in treatment of transgenic HD mice (Andreassen et al., 2001; 
Ferrante et al., 2000) (Koroshetz et al., 1997); creatine and co-enzyme Q are currently in 
clinical trials.  HD excitotoxicity can be targeted with NMDA receptor antagonists and 
metabotropic glutamate receptor agonists (Orlando et al., 1997), as well as glutamate 
release inhibitors such as lamotrigine (Kremer et al., 1999) and riluzole (Rosas et al., 
1999; Seppi et al., 2001).  Riluzole and paroxetine also increase levels of neurotrophins 
such as BDNF (Mizuta et al., 2001; Walker and Raymond, 2004), potentially rescuing 
BDNF deficiencies seen in HD. 
Transgenic Drosophila disease models have proven invaluable for the 
development of therapeutic strategies.  Many cellular pathways are conserved between 
humans and flies (Adams et al., 2000), and the ease of handling and sophisticated 
genetic approaches available in Drosophila models enable the design of unbiased 
genetic screens that can be used to identify new molecular targets for therapy.  Screens 
to identify mediators of polyQ toxicity have identified several genes, including 
chaperones, RNA processing proteins, and chromatin-remodeling proteins (Fernandez-
Funez et al., 2000; Kazemi-Esfarjani and Benzer, 2000), and have led to the design of 
therapeutic interventions that rescue toxicity in both fly and mammalian disease models 
(Hay et al., 2004; Hockly et al., 2003a; Steffan et al., 2001; Warrick et al., 1999). 
In addition, Drosophila disease models can be used for high-throughput and 
rapid screening of candidate therapies before testing in mammals.  The ability to rescue 
disease phenotypes in fly models with human drug treatments (Min and Benzer, 1999) 
suggests that the inverse may also be true – that therapies found to be effective in fly 
models may be beneficial in treatment of human diseases.  In fly models of polyQ 
diseases, many characteristics of the human disorders are conserved: expression of 
expanded polyQ proteins in flies leads to formation of insoluble intracellular inclusions, 
and flies develop a late-onset, progressive disorder that ends in premature death 
(Fernandez-Funez et al., 2000; Jackson et al., 1998; Kazantsev et al., 2002; Marsh et 
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al., 2000; Takeyama et al., 2002; Warrick et al., 1999).  As in humans, the length of the 
polyQ repeat determines the severity of disease pathogenesis, and similar thresholds of 
repeat length are required for disease manifestation (Fernandez-Funez et al., 2000; 
Jackson et al., 1998; Kazemi-Esfarjani and Benzer, 2000; Marsh et al., 2000; Takeyama 
et al., 2002; Warrick et al., 1999).  Many therapies that have proven beneficial in 
mammalian HD models have also been effective in transgenic HD flies, including HDAC 
inhibitors (Steffan et al., 2001); (Zhao et al., 2005), Congo Red (Apostol et al., 2003), 
cystamine (Apostol et al., 2003), small peptides (Kazantsev et al., 2002; Nagai et al., 
2003), chaperones (Iijima-Ando et al., 2005; Kazemi-Esfarjani and Benzer, 2000), and 
intracellular antibodies (Wolfgang et al., 2005).  This evidence for conservation of 
disease mechanisms between mammals and flies indicates that Drosophila models of 
HD will be useful for the development and testing of potential therapies.   
Our Drosophila HD model provides an ideal in vivo environment in which to test 
chemical and molecular mediators of mutant Htt-induced pathology, especially in the 
cytoplasm and neurites.  This chapter focuses on use of transgenic Drosophila lines 
expressing a 588 aa N-terminal fragment of mutant Htt to test the effects of expression 
of an intracellular antibody against Htt on aggregation and toxicity. 
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Materials and Methods 
 
S2 Cell Transfection and Analysis 
cDNAs for mRFP-HttQ15 and mRFP-HttQ138 were subcloned into the BamH1 
and EcoRI  (blunt end ligation) sites of the pSR11 vector.  cDNA for the VL12.3 intrabody 
was subcloned into the pPL17 vector.  Constructs were transfected with 50 μL 
cytofectene (BioRad) into Drosophila S2 cells using the BioRad Liposome Mediated 
Transfection Protocol.  4 μG of construct DNA were used per 5 mL S2 cell culture for 
single transfections while 4 μG of each construct were used for double transfections.  
After 72 hours, 20 μL cell suspensions were fixed with 3.7% formaldehyde in 1 x PBT, 
then mounted on slides with 50% glycerol in 1 x PBS.  Visualization of slides was 
performed on a Pascal confocal microscope (Zeiss). 
 
Morphological Analysis   
Wandering 3rd instar larvae reared at 25oC were dissected as described 
(Rieckhof et al., 2003).  Visualization and quantification were performed on a Pascal 
confocal microscope (Zeiss). 
 
Glue Secretion Assay 
Pupae reared at 25oC were isolated shortly after pupariation and adhered to 
slides with ventral sides facing up using double-sided tape.  Visualization and 
quantification were performed on a Pascal confocal microscope (Zeiss). 
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Results 
 
VL12.3 is a single-domain intracellular antibody, or intrabody, against the first 20 
aa of the Htt protein (Colby et al., 2004a).  Most intrabodies to date have been isolated 
under oxidizing conditions that allow the formation of stabilizing disulfide bonds between 
intrabody cysteine residues; in the reducing environment of the cytoplasm, however, 
disulfide bonds are less readily formed, compromising the stability and effectiveness of 
intrabodies within the cell.  VL12.3 has been optimized for high intracellular efficacy at 
low expression levels by increasing its affinity for Htt in the absence of a disulfide bond.  
Expression of VL12.3 in neuronal and yeast HD models inhibits aggregation and rescues 
toxicity.  To determine whether mutant Htt-mediated aggregation and toxicity are 
reduced in vivo, we have generated double transgenic flies that express both mRFP-
HttQ138 and the VL12.3 intrabody. 
 
Expression of the intrabody in S2 cells reduces aggregate formation 
Although it has not been resolved whether mutant Htt-induced toxicity is 
dependent on aggregate formation, suppression of aggregation has been correlated with 
rescue of HD phenotypes for many prospective therapies.  To determine the effect of 
intrabody expression on mutant Htt aggregation at the cellular level, levels of 
aggregation were compared between Drosophila S2 cells transiently transfected with 
mRFP-HttQ138 alone or with both mRFP-HttQ138 and the VL12.3 intrabody.  While 
expression of mRFP-HttQ138 alone resulted in formation of large cytoplasmic 
aggregates (Fig. 1A), mRFP-HttQ138 coexpressed with the intrabody exhibited diffuse 
localization throughout the cytoplasm (Fig. 1B).  Visualization of the intrabody shows 
perinuclear as well as cytoplasmic localization, with increased density at areas of mRFP-
HttQ138 density, indicating a direct interaction between the intrabody and Htt (Fig. 1C). 
 
Expression of the intrabody in vivo reduces mutant huntingtin aggregation in 
neuronal and non-neuronal cells  
To assess whether aggregation of mutant Htt is also inhibited by the intrabody in 
vivo, transgenic lines expressing mRFP-HttQ138 alone or mRFP-HttQ138 with the 
intrabody were crossed to lines expressing the pan-neuronal C155 elav-GAL4 driver.  3rd 
instar larval offspring of the crosses were imaged using confocal microscopy.  As 
observed in S2 cells, in comparison to mRFP-HttQ138 expression alone (Fig. 2A),
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FIGURE 1. Intrabody expression suppresses mutant Htt aggregation in Drosophila 
S2 cells.  (A) mRFP-HttQ138 forms large cytoplasmic aggregates (white).  (B) 
Coexpression of the VL12.3 intrabody with aggregates results in diffuse cytoplasmic 
localization of mRFP-HttQ138 (white).  (C) Intrabody localization (green) is cytoplasmic 
and perinuclear, and is concentrated at sites of mRFP-HttQ138 density (magenta), 
indicating an interaction between the intrabody and mutant Htt. 
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FIGURE 2. Intrabody expression suppresses mutant Htt aggregation in vivo in 
Drosophila.  Compared to expression of mRFP-HttQ138 alone (A), coexpression of the 
intrabody (green) reduces aggregate number and increases diffuse localization of 
mRFP-HttQ138 (red) in the CNS of wandering 3rd instar larvae (B).  Aggregation of 
mRFP-HttQ138 (red) is also dramatically suppressed in salivary gland cells (C, D) and in 
the epidermis (E, F). 
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FIGURE 3. The intrabody does not rescue functional defects in salivary gland glue 
secretion in Drosophila.  (A) Diagram of normal glue secretion during pupariation.  
Expression of the glue protein fused to GFP enables in vivo imaging of secreted glue. 
(B) Secretion of glue-GFP (green) is normal in pupae expressing mRFP-HttQ15 
(magenta).  Arrows indicate secreted glue.  (C) In pupae expressing mRFP-HttQ138 
(magenta), secretion of glue-GFP (green) is strikingly decreased.  (D) Coexpression of 
the intrabody in pupae expressing mRFP-HttQ138 (magenta) does not restore secretion 
of glue (green) to normal levels and does not rescue salivary gland dysfunction. 
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intrabody expression reduced aggregate number and increased diffuse mRFP-HttQ138 
localization in the CNS (Fig. 2B).  Suppression of aggregation was especially dramatic in 
the salivary glands; while large, distinct cytoplasmic aggregates are seen in salivary 
gland cells of larvae expressing mRFP-HttQ138 alone (Fig. 2C), coexpression of the 
intrabody resulted in diffuse, cytoplasmic localization of mRFP-HttQ138 with almost 
complete elimination of aggregates (Fig. 2D).  Coexpression of mRFP-HttQ138 with the 
intrabody also reduces aggregate formation in the epidermis (Fig. 2F) in comparison to 
expression of mRFP-HttQ138 alone (Fig. 2E). 
 
Intrabody expression does not rescue mutant huntingtin-induced defects in 
salivary gland secretion in Drosophila 
Large cytoplasmic aggregates are abundant in the salivary glands of mRFP-
HttQ138-expressing larvae (Fig. 2C), and cause a defect in the secretion of GFP-tagged 
glue from the salivary glands during pupariation (see Chapter 3).  To determine whether 
this defect is rescued by intrabody expression, pupae expressing mRFP-HttQ138, glue-
GFP, and the intrabody with the C155 elav-GAL4 driver were compared to pupae 
expressing mRFP-HttQ138 and glue-GFP alone and pupae expressing mRFP-HttQ15 
and glue-GFP.  While coexpression of mRFP-HttQ15 and glue-GFP leads to normal 
pupal glue secretion, with glue-GFP visible on the ventral side of the pupal case (Fig. 3A 
& B), coexpression of mRFP-HttQ138 with glue-GFP results in a lack of secreted glue 
(Fig. 3C).  Expression of the intrabody does not increase glue-GFP secretion in mRFP-
HttQ138-expressing pupae (Fig. 3D), indicating that although intrabody expression 
strikingly reduces aggregates in the salivary gland, the intrabody does not rescue the 
mutant Htt-mediated functional defect in salivary gland secretion of glue during 
pupariation in Drosophila. 
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Discussion 
 
Recent studies have highlighted the potential of intracellular antibodies, or 
intrabodies, in the treatment of neurodegenerative diseases.  Intrabodies can be isolated 
and affinity matured for binding to specific targets in yeast or phage display libraries, and 
may be especially suited for treatment of single-gene disorders such as Huntington’s 
disease.  Binding of an intrabody to a target protein, such as mutant Htt, may disrupt its 
interactions with other binding partners or alter protein stability, and may also be used to 
redirect proteins to specific subcellular compartments (Miller and Messer, 2005).  
Expression of intrabodies against the huntingtin protein has been shown to inhibit 
aggregation in various cell (Lecerf et al., 2001) and brain slice (Murphy and Messer, 
2004) HD models, and has extended lifespan and delayed neurodegeneration in vivo in 
a Drosophila model of HD (Wolfgang et al., 2005). 
One limitation of intrabody use for therapeutic purposes has been the limited 
intracellular efficacy of intrabodies isolated in in vitro environments.  To optimize 
intracellular efficacy, the VL12.3 intrabody was isolated and matured for binding affinity to 
Htt in the absence of the stabilizing disulfide bond in order to select for intrabody 
properties independent of the redox environment (Colby et al., 2004a).  The VL12.3 
intrabody suppresses aggregate formation and rescues toxicity in neuronal and yeast 
HD models.  To determine whether the intrabody has a similar effect in vivo, we 
generated transgenic lines expressing a 588 aa N-terminal fragment of mutant Htt with 
or without coexpression of the intrabody.  In the presence of the intrabody, mutant Htt 
aggregates were greatly reduced in both neuronal and non-neuronal tissues, while levels 
of diffuse mutant Htt in the cytoplasm were visibly increased (Fig. 2). 
Because aggregate formation has not been confirmed as a toxic step in HD 
pathogenesis, prospective therapies are also tested for ability to rescue mutant Htt-
induced phenotypes, such as motor defects and neurodegeneration.  Our Drosophila HD 
model exhibits an abundance of mutant Htt aggregates in the salivary gland, and 
demonstrates a clear defect in salivary gland secretion of glue during pupariation.  
Expression of the VL12.3 intrabody dramatically reduced mutant Htt aggregation in the 
salivary gland, but did not rescue the secretion defect (Figure 3), indicating that mutant 
Htt-mediated toxicity may be aggregate-independent in this cell type.  Future studies 
may reveal rescue of other functional phenotypes (see Future Directions).  The 
conformational specificity of similar intrabodies isolated through binding affinity to Htt 
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may also be used for validation of sites on the mutant protein that can be used as 
targets for rational drug design. 
Our Drosophila HD model recapitulates the inhibition of aggregation seen in 
cellular and yeast HD models expressing the VL12.3 intrabody.  While salivary gland 
secretion is not rescued, the effects of intrabody expression can be tested on many 
other mutant Htt-induced phenotypes characterized in our model, including reduced 
lifespan, motor defects, and neurodegeneration of photoreceptor cells.  The broad 
characterization of cellular and functional phenotypes in our Drosophila HD model make 
it ideal for the testing of potential therapies, allowing a multimodal analysis of therapeutic 
effect in vivo. 
 
 
 179
Future Directions 
 
Although salivary gland secretion defects are not rescued by intrabody 
expression, results in this non-neuronal tissue should not be used to predict the effect of 
the intrabody on phenotypic defects more common to HD animal models. Future studies 
will test the effects of intrabody expression on other defects induced by expression of a 
588 aa N-terminal fragment of mutant Htt in Drosophila, including reduced lifespan and 
neurodegenerative rough-eye phenotypes.   
Adult flies expressing mRFP-HttQ138 with a 2nd chromosome pan-neuronal elav-
GAL4 driver undergo a dramatic, dose-dependent reduction in lifespan (see Chapter 3), 
with a decrease in T50 (time at which 50% of the culture has died) of over 70% in 
comparison to controls.  This provides a precise assay with which to analyze intrabody 
effects on a mutant Htt-induced premature death phenotype.  Rescue or partial rescue of 
reduced lifespan will indicate that intrabody expression can reduce toxicity as well as 
aggregation in an in vivo model of Huntington’s disease. 
 Eye-specific expression of a 548 aa N-terminal fragment of mutant Htt (Htt-Q128) 
can be driven with the GMR-GAL4 driver, and leads to a rough-eye phenotype with loss 
of pigmentation, abnormal bristle pattern, and retinal photoreceptor degeneration (see 
Chapter 2).  The rough-eye phenotype is a sensitive assay that can detect small 
changes in toxic insult to the eye, and should allow visualization of any rescue of eye 
defects by intrabody expression.  A decrease in the rough-eye phenotype or in the 
degeneration of photoreceptors as viewed through pseudopupil analysis will provide 
evidence for intrabody rescue of mutant Htt-mediated toxicity. 
 Further analysis of intrabody effects on aggregate formation in different tissues 
may also be useful in assessing intrabody efficacy and function.  Correlating changes in 
aggregate number with enhancement or suppression of functional defects may shed 
light on the role of mutant Htt aggregation in disease toxicity.  While expression of the 
intrabody in cell and yeast HD models suggests that inhibition of aggregation may play a 
role in rescuing mutant Htt-induced toxic effects, in vivo analysis may show that 
aggregate suppression is unrelated to functional rescue, or may even intensify defective 
phenotypes, providing evidence that aggregates are not the toxic form of the mutant Htt 
protein. 
 A key strength of Drosophila disease models is the ability to perform second-site 
modifier screens to identify molecular pathways involved in disease pathogenesis, 
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leading to the discovery of new targets for therapy.  Expression of the 588 aa N-terminal 
fragment of mutant Htt in our Drosophila HD model results in pharate adult lethality, 
enabling large-scale screens for genetic suppressors of the lethal phenotype.  In 
addition, the mRFP tag on the mutant Htt fragment allows easy screening for 
suppressors and enhancers of aggregation in live 3rd instar larvae.  Future screens can 
thus be designed to isolate genetic modifiers that affect aggregation, toxicity, or both.  In 
summary, our Drosophila model of HD will be valuable both for testing of candidate 
therapies and for discovery of new therapeutic targets and strategies. 
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